

Review

Unravelling monocyte functions: from the guardians of health to the regulators of disease

Alexander Mildner^{1,2,*}, Ki-Wook Kim^{3,*} and Simon Yona^{4,*} 

¹MediCity Research Laboratory, University of Turku, Turku, Finland

²InFLAMES Research Flagship, University of Turku, 20014 Turku, Finland

³Department of Pharmacology and Regenerative Medicine, University of Illinois College of Medicine, Chicago, Illinois, USA

⁴Institute of Biomedical and Oral Research, Faculty of Dental Medicine, Hebrew University, Jerusalem, Israel


*Contributed equally.

*Corresponding authors. Department of Pharmacology and Regenerative Medicine, University of Illinois College of Medicine, Chicago, USA. E-mail: kiwook@uic.edu; MediCity Research Laboratory, University of Turku, Turku, Finland. E-mail: alexander.mildner@utu.fi; Institute of Biomedical and Oral Research, Faculty of Dental Medicine, Hebrew University, Jerusalem, Israel. E-mail: s.yona@mail.huji.ac.il

Abstract

Monocytes are a key component of the innate immune system. They undergo intricate developmental processes within the bone marrow, leading to diverse monocyte subsets in the circulation. In a state of healthy homeostasis, monocytes are continuously released into the bloodstream, destined to repopulate specific tissue-resident macrophage pools where they fulfil tissue-specific functions. However, under pathological conditions monocytes adopt various phenotypes to resolve inflammation and return to a healthy physiological state. This review explores the nuanced developmental pathways and functional roles that monocytes perform, shedding light on their significance in both physiological and pathological contexts.

Graphical Abstract



Keywords: monocytes, macrophages, inflammation, cancer, haematopoiesis and metabolic disease

Received 15 May 2024; revised 6 August 2024; accepted 29 August 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abbreviations: Arg: arginase; ApoE: apolipoprotein E; BrdU: bromodeoxyuridine; CDP: common DC progenitor; cMoP: common monocyte progenitors; CMP: common myeloid progenitors; CNS: central nervous system; CpG: DNA molecules cytosine triphosphate deoxynucleotide followed by a guanine triphosphate deoxynucleotide; CSF1: colony stimulating factor 1, aka; macrophage colony-stimulating factor (M-CSF); CSF2: colony stimulating factor 2: aka; granulocyte-macrophage colony-stimulating factor (GM-CSF); DC: dendritic cell; DTR: diphtheria toxin receptor; EAE: experimental autoimmune encephalomyelitis; EMP: erythro-myeloid progenitors; GFP: green fluorescent protein; GMP: granulocyte-monocyte progenitor; HIF: hypoxia-inducible factor; HSC: haematopoietic stem cells; ICAM: intercellular adhesion molecules; IFN: interferon; IL: interleukin; KEGG: Kyoto encyclopaedia of genes and genomes; LAM: lipid-associated macrophages; LFA: lymphocyte function-associated antigen; LPS: lipopolysaccharides; MBP: myelin basic protein; MDP: monocyte/DC progenitors; MHC: major histocompatibility complex; MMTV-PyMT: mouse mammary tumour virus-polyoma Virus middle T antigen; MMP: metalloproteinase; MPO: myeloperoxidase; MPP: multi-potent progenitors; MPS: mononuclear phagocyte system; NOS: nitric oxide synthase; NSCLC: non-small cell lung cancer; oxLDL: oxidized low-density lipoprotein; PDAC: pancreatic ductal adenocarcinoma; pDC: plasmacytoid dendritic cells; PGE₂: prostaglandin E₂; ROS: reactive oxygen species; scRNA-seq: single cell RNA sequencing; SPF: specific pathogen-free; TAM: tumour-associated macrophages; Th: T helper; TLR: toll like receptor; TME: tumour microenvironment; TNF: tumour necrosis factor; VEGF: vascular endothelial growth factor; WT: wild type.

Introduction

Monocytes constitute one component of the ‘mononuclear phagocyte system’ (MPS) together with macrophages and dendritic cells (DC) [1–3]. Circulating monocytes comprise approximately 10% of peripheral leukocytes in humans and around 4% in mice. It was in 1910 when Artur Pappenheim coined the term ‘the monocyte’ with the goal of consolidating various previously described cell types into a single overarching leukocyte population [4]. Subsequently, the definition of the monocyte evolved to become more stringent, exclusively referring to Ehrlich’s transitional cell [5–9]. Ehrlich described his ‘transitional cell’ featuring a nucleus with a kidney bean-shaped appearance and postulated that these cells are an intermediate state in the developmental process of polymorphonuclear neutrophils. Nevertheless, the introduction of flow cytometry revolutionized immunology and haematology, allowing for the recognition of several monocyte subsets that are conserved across different species [10]. Distinct monocyte subsets were initially identified based on their morphological characteristics and varying expression of CD14 and CD16 in humans [11], a landmark breakthrough in monocyte biology. The combination of CD14 and CD16 membrane expression on human monocytes enabled the classification of three principal human monocyte subsets: CD14⁺CD16⁻ monocytes, also termed classical monocytes, CD14⁺CD16⁺ intermediate, and CD14^{Low}CD16⁺ non-classical monocytes. In mice, classical monocytes are defined by the membrane expression Ly6C^{Hi} CCR2⁺ CD62L⁺ CD43^{Low}, while non-classical monocytes also described as ‘patrolling monocytes’ are defined as Ly6C^{Low} CCR2^{Low} CD62L⁻ CD43⁺ [12–15] (Table 1). Of note, *Cx3cr1*-driven GFP levels are also often used to characterize and distinguish classical monocytes (*Cx3cr1*^{Low}) from their non-classical counterparts (*Cx3cr1*^{Hi}) [12], but this distinction reflects the *Cx3cr1* promoter activity and is only suitable for monocyte subset identification in *Cx3cr1*^{Gfp/+} mice. The CX₃CR1 membrane protein levels on both monocyte subsets appear similar in wild-type mice [16, 17]. The advent of high dimensional cytometry and single-cell RNA-sequencing has further refined the definition of monocyte populations and their origin.

Monocytes have long been considered the primary precursor cells for macrophages, capable of replenishing tissue-resident subsets as and when required. Recent mouse studies indicate that monocytes contribute to almost all tissue-resident macrophage pools including the blood (as non-classical monocytes), intestine [18, 19], heart [20, 21], interstitial lung [22–24], serous cavities [25] and possibly even the brain [26]. However, the contribution of monocytes to these pools differs in intensity (from high to low, in the order described) and these conclusions were derived from inbred laboratory mice maintained under specific

pathogen-free conditions. Despite potential paradigm shifts in our understanding of the monocyte-to-macrophage development theory—Ralph van Furth *et al.*, recognized in 1972 when defining the mononuclear phagocyte system (MPS) that macrophages could be classified as either free or fixed. They described fixed macrophages as ‘*probably of monocyte origin, but definitive proof has not been obtained (...) the morphology and functional behaviour (...) justify their inclusion in the MPS*’. Hence, 50 years ago, it was already acknowledged that certain macrophage populations required continuous monocyte repopulation, while others were potentially more-or-less independent of monocytes [2], a hypothesis that has stood the test of time.

As inflammation and injury ensue, the long-term replacement of embryo-derived macrophages by monocyte counterparts may occur [27]. It remains to be shown how monocytes contribute to tissue-resident macrophage pools in ‘wild’ mammals that regularly experience infections and day-to-day injuries. Understanding how monocytes contribute to the macrophage pool remains challenging to untangle in a human setting. For instance, Langerhans cells in the skin have been shown to remain of donor origin even a decade after a transplant [28]. However, contrasting findings show that following bone marrow transplantation, the majority of Langerhans cells are derived from the donor within just three months [29–31]. It is worth mentioning that the outcomes of these studies could be influenced by environmental, genetic, and/or therapeutic factors, which can create a niche for monocyte-derived cells. Therefore, injury, infection, or ageing in a specific tissue will determine the need to substitute embryonic macrophages with monocyte-derived cells. In addition to their ability to differentiate into tissue-resident macrophages, monocytes serve as an emergency squad during pathological conditions. Accordingly, monocyte accumulation is a common feature of various diseases. Their presence signifies that the homeostatic state has not yet been fully restored.

In this review, we explore the notion that the monocyte has evolved to assist and help, although this may sometimes lead to undesirable consequences.

Monocyte development and heterogeneity

The process of haematopoiesis was proposed by Alexander Maximow at the turn of the 20th century to be a highly controlled process in which common precursors ultimately generate disparate populations of leukocytes [32]. Ninety years after Maximow’s model of haematopoiesis and three decades after Till and McCulloch delineation of the bone marrow’s ability to generate diverse haematopoietic colonies in the spleen [33], mouse single-cell transplantation experiments using purified haematopoietic stem cells (HSCs)

revealed the sustained reconstitution of both myeloid and lymphoid lineages [34]. While these studies showcased the powerful self-renewal capability and multi-potent differentiation potential of HSCs in irradiated mice, the contribution of HSCs to daily haematopoiesis in unperturbed adult bone marrow appears restricted [35–37]. Instead, proliferative short-term HSCs and multi-potent progenitors (MPP) serve as long- and intermediate-term amplifying cells, respectively, and are the main drivers of steady-state haematopoiesis during most of adulthood (Fig. 1). MPPs could be categorized into MPP2-4 oligo-potent states of which MPP3 were mainly a myeloid-biased progenitor [39]. MPP3 can subsequently differentiate into common myeloid progenitors [40] with

megakaryocyte/erythrocyte and myeloid potential [41]. The megakaryocyte/erythrocyte differentiation potential is lost in the more restricted granulocyte-monocyte progenitor (GMP) that develops from the CMP (Fig. 1). *Cx3cr1*-expressing monocyte/DC progenitors (MDP) were identified and proposed to be the exclusive precursor of monocytes and conventional dendritic cells (cDC), but not neutrophils [42–44], although conflicting results concerning neutrophil potential within the MDP state were raised [45]. MDPs differentiate into unipotent, proliferative common monocyte progenitors (cMoP) that finally develop into Ly6C⁺ monocytes [46].

However, this prevalent hierarchical view of monocyte and cDC development was recently challenged. Observations by




Figure 1. Monocyte development. Haematopoiesis begins with a small number of active haematopoietic stem cells (HSC), which populate a reservoir of multipotent progenitors (MPPs); (indicated by the numbers 2–4 [38]) that already exhibit tendencies toward specific cell lineages. As differentiation continues, precursor populations become progressively more restricted towards specific fates and are classified according to their cellular output and surface characteristics into various precursor subsets (depicted by rectangles), which sometimes exhibit a shared overlapping surface marker profile. Note that the majority of classical monocytes derive from granulocyte-monocyte precursors (GMP), while only a small fraction of Ly6C⁺ expressing cells derive from monocyte and dendritic cell progenitors (MDP). Several open questions remain during monocyte development depicted in grey with question marks: **(a)** Do MDP-derived monocytes go through a common monocyte progenitor (cMoP) stage? **(b)** What is the relationship between pro-DC3 and MDP-derived monocytes? **(c)** GMP- and MDP-derived monocytic cells can experimentally lose Ly6C expression, but do both convert into non-classical monocytes under physiological conditions? Further abbreviations: CLP, common lymphoid progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; DC, dendritic cell; cDC, conventional DC; pDC, plasmacytoid DC. Figure adapted from [38] with permission.

single cell RNA-sequencing (scRNA-Seq) indicated the existence of cells with a gene signature reflecting monocytes or neutrophils already within the GMP and CMP state [47]. Interestingly, the murine MDP population was also identified by flow cytometry within the CMP compartment and may directly arise from an *Flt3*-expressing CMP and not exclusively from a GMP [48]. Seminal studies comparing two distinct inflammatory agents, LPS or CpG [48], indicated that monocytes can arise from two alternative paths: One monocyte differentiation route involves GMPs (also termed ‘neu- or neutro-like monocytes’), while another monocytic subset arises from MDPs (‘DC-like monocytes’), respectively. This was confirmed by clonal barcoding and fate mapping studies highlighting the convergent differentiation trajectories of monocytes [49]. It was also noted under homeostatic conditions that Ly6C-expressing monocytes can be further segregated into MHCII⁺ and MHCII⁻ cells in mice (immgen [14, 50, 51];). The murine MHCII-expressing cells were characterized by a gene profile that corresponds to MDP-derived cells under pathological conditions, e.g. *Cd209a* and MHCII-related genes [50, 51]. The generation of the *Ms4a3*-lineage tracing mouse shed new light on the origin of monocytes. In this mouse line, all cells of GMP origin are labelled when crossed to a reporter line [52]. This system revealed that a large proportion of monocytes (~95% of CD115⁺ cells) are labelled in *Ms4a3*^{Cre} *Rosa26*^{LSL-tdTomato} fate mapping mice, while only a small subset (~3–5% of CD115⁺ cells) remain unlabelled [52]. This demonstrates that the majority of monocytes descend from GMPs, which is in contrast to previous studies that clearly showed the potential of MDPs to give rise to Ly6C⁺ cells when adoptively transferred into the blood stream of recipient mice [53]. These data can be reconciled by assuming a dual origin of monocytes in which both GMPs and MDPs have the potential to develop into circulating Ly6C-expressing cells following adoptive transfer. Recent fate mapping and scRNA-Seq experiments further explored the origin of unlabelled Ly6C⁺ cells in *Ms4a3*^{Cre} *Rosa26*^{LSL-tdTomato} mice and indicated that these cells correspond to the murine pro-DC3 subset rather than monocytes [23]. The expression of DC-related genes such as *Flt3*, *Zbtb46*, and the superior antigen presentation capabilities support these findings. A CD135⁺ Ly6C⁺ cell population could also be identified in WT mice, which showed antigen-presenting capacity [54]. However, *Flt3* and *Zbtb46* expression could not be detected in another study that identified CD319⁺ MDP-derived cells in the double reporter system *Ms4a3*^{Cre} *Rosa26*^{LSL-tdTomato} *Cx3cr1*^{Gfp} [55] (Fig. 1; Table 1), indicating that MDP-derived monocytes and pro-DC3 are two independent cell types. Surprisingly though, the transcriptomic signatures of MDP-derived monocytes by Trzebanski *et al.* [55], show a remarkable overlap with pro-DC3 cells reported in Liu *et al.* [23], while CD177⁺ GMP-derived monocytes correspond to classical monocytes [55] (Table 1). It remains to be resolved if the *Cd209a*⁺ cells [50, 51] are either Ly6C⁺ classical monocytes or pro-DC3 cells [23] (Fig. 1). Curiously, both Ly6C⁺ GMP- and MDP-derived monocyte populations lose Ly6C expression when adoptively transferred into the bloodstream [55], which raises the question if both subsets convert into Ly6C^{Low} monocytes? If so, why do two alternative precursor fates give rise to one homogenous non-classical monocyte compartment [50]? Independent of these artificial transfer experiments, it is important to know, if MDP- or

Table 1: Phenotype of monocyte subsets

Cell type	Surface markers (protein level)	Transcription level	Precursor
Mouse (CD115 ⁺ , CD11b ⁺)			
Classical monocytes	Ly6C ^{high} , CD62L ⁻ , CCR2 ⁺ , CD177 ⁺	<i>Cx3cr1</i> -Gfp ^{low} , <i>Chil3</i> , <i>Elane</i> , <i>Mpo</i>	<i>Ms4a3</i> ⁺ (GMP)
Non-classical monocytes	Ly6C ^{low} , CD62L ⁺ , CCR2 ⁻ , CD43 ⁻ , CD16.2 ⁺	<i>Cx3cr1</i> -Gfp ^{high} , <i>Nr4a1</i>	Ly6C ^{high} monocytes
Pro-DC3	Ly6C ⁺ , CD135 ⁺ , CD45RB ⁺	<i>Cd74</i> , <i>Cd209a</i> , <i>Zbtb46</i>	<i>Zbtb46</i> ⁺ , <i>Ms4a3</i> ⁻ Ly6C ⁺ (MDP)
<i>Cd209a</i> ⁺ cells	Ly6C ⁺ , CD62L ⁺ , CCR2 ⁺ , CD319 ⁺	<i>Cd74</i> , <i>Cd209a</i> , <i>Clec10a</i>	<i>Zbtb46</i> ⁻ , <i>Ms4a3</i> ⁻ (MDP)
Classical monocytes	CD88 ⁺ , CD89 ⁺ , CD14 ⁺ , CD16 ⁻ , CCR2 ⁺	<i>Sl100a8/9/12</i> , <i>Vcam</i>	cMoP (CLEC12A ^{high} CD64 ^{high}) within the GMP
Intermediate monocytes	CD88 ⁺ , CD89 ⁺ , CD14 ⁺ , CD16 ⁺ HLADR ^{High}	<i>Plac8</i> , <i>Hla-dma</i> , <i>Prdm1</i>	Classical monocytes
Non-classical monocytes	CD88 ⁺ , CD89 ⁺ , CD14 ^{low} , CD16 ⁺	<i>Cdkn1c</i> , <i>Tcf712</i>	Intermediate monocytes
DC3	CD88 ⁻ , CD89 ⁻ , CD123 ⁻ , FcεR1a ⁺ , CD1c ⁺ , CD5 ⁻ , CD163 ⁺ , CD14 ⁺	<i>Sl100a8/9</i> , <i>Vcam</i> , <i>Lyz</i> , <i>Anaxa1</i>	IRF8 ^{lo} (CD33 ⁺ GMP)

GMP-derived cells exhibit different functions under healthy homeostasis and during pathology. When GMPs and MDPs are injected into the bloodstream of mice with experimental autoimmune encephalomyelitis (EAE), both progenitor cells have the potential to develop into indistinguishable pathogenic subsets in the inflamed central nervous system (CNS) [56], indicating a similar fate when transferred into the same niche (blood) during inflammatory conditions. However, inflammatory stimuli such as LPS or CpG injections favour the generation of GMP- or MDP-derived cells, respectively [48]. Also, the injection of purified GMP- or MDP-derived cells into an empty macrophage niche (in diphtheria toxin-treated *Cx3cr1^{DTR}* bone marrow chimera) gave different results in terms of tissue colonization: while intestinal macrophages were derived equally from either a GMP or MDP progenitor, only GMP descendants efficiently differentiated into meningeal dura mater macrophages [55]. It remains to be determined whether MDP-derived cells belong to the DC family or if they will revert to being classified as a monocyte subset. Future studies will help unify the nomenclature of these populations and hopefully reconcile these conflicting results, as recently attempted in humans. In this setting, DC3 was originally delineated within the human classical monocyte gate, but refinements in flow cytometric analysis helped to identify human DC3 cells and thereby allowed their clear separation from classical monocytes [57–60] (Table 1). However, they still present a challenge for enrichment strategies [61].

Within the bone marrow, monocytes reside near sinusoidal endothelial cells and leptin receptor-expressing perivascular mesenchymal stromal cells. The cells within this niche contribute to the maintenance of monocytes by providing CSF1 [62]. In contrast to the situation in mice, human monocytes rely on FLT3L as patients with a rare *FLT3LG*-deficiency presented a strong reduction of all monocyte subsets in the blood and bone marrow [63]. This phenotype can be attributed to the role of FLT3L in myeloid precursor differentiation and maintenance in the bone marrow [63], but it is unclear if mature human monocytes utilize FLT3L for their survival. Immature bone marrow CXCR4⁺ pre-monocytes undergo further proliferation and differentiate Ly6C^{Hi} CXCR4⁺ monocytes, which up-regulate the chemokine receptor CCR2 [64]. This increased membrane expression of CCR2 is important for the bone marrow egression of classical monocytes through the interaction with CCL2 and CCL7, in mice [65]. However, *CCR2*-deficiency in humans did not affect classical monocyte numbers in the circulation and argues for an alternative egression pathway in humans [24]. In mice, the CCR2-dependent release of monocytes from the bone marrow into the circulation can be influenced by low concentrations of Toll-like receptor (TLR) ligands present in the bloodstream. It was shown that bone marrow mesenchymal stem cells and CXCL12-abundant reticular cells increase CCL2 expression in response to various bacteria-derived TLR ligands, thereby desensitize CXCR4 signalling and inducing the TLR4-dependent monocyte mobilization into the blood [66, 67]. This mechanism secures the rapid mobilization of classical monocytes in the presence of inflammatory signals and demonstrates, how quickly monocyte numbers can adapt to pathological situations. Classical monocytes may also re-enter the bone marrow during circadian oscillation and fasting in a CXCR4-dependent manner [64, 68]. Compared to classical monocytes, non-classical monocytes traffic from the bone

marrow into the blood in a CCR2-independent fashion, but they utilize S1PR5 signalling [69].

Taken together, recent studies have revealed that classical monocytes arise from two alternative paths (either through GMP or MDP) under homeostatic and inflammatory conditions. Future research will reconcile these findings and establish a unified understanding of the monocytes that arise from distinct progenitors.

Monocyte plasticity under homeostatic conditions

The prevailing theory concerning the destiny of classical monocytes upon entering the peripheral circulation is that they possess significant potential for further development before reaching a fully differentiated state [70]. Epigenetic analysis of mouse classical monocytes reveals that this monocyte subset is not characterized by a specific chromatin landscape compared to non-classical monocytes. Only a minor fraction of genes are uniquely accessible and carries histone modifications specific to classical monocytes. In contrast, non-classical monocytes possess a higher degree of unique *de novo* established regulatory elements comprising classical macrophage genes including *Cd36* and *Pparg* [50]. Similar to other tissue-resident macrophage populations, non-classical monocytes are also CSF1 dependent, while the numbers of short-lived classical monocytes are virtually unaffected in mice with a deficient CSF1 signalling pathway [71]. Adoptive transfer of classical murine monocytes into the circulation or following bromodeoxyuridine (BrdU) pulse labelling revealed that classical monocytes quickly lose their phenotypical characteristics and differentiate into non-classical monocytes between 24 and 48 hours [27, 50, 72]. In humans, this developmental profile is conserved, demonstrated through stable isotope labelling. Classical monocytes transition into intermediate and subsequently non-classical monocytes within 4 days [73, 74]. These data suggest that classical monocytes represent a more immature ephemeral monocyte subset that either extravasate into tissues or develops into terminally differentiated non-classical monocytes. The mechanisms involved in how classical convert into non-classical monocytes and how the subsets differ with respect to metabolism and tissue recruitment will be discussed in the following subsections.

Monocyte conversion

The factors that dictate classical monocyte conversion remain to be fully elucidated. However, recent findings suggest that endothelial niches or micro-injuries could potentially play a role in facilitating classical monocyte conversion into cells adhering to the endothelium and subsequently maturing into non-classical monocytes with reparative abilities. Elegant *in vitro* studies have pointed to an important role in Notch2-DLL1 interaction for this ‘default’ monocyte conversion. When MDP or cMoP were cultured in the presence of *Dll1*-expressing OP9 cells, descendants with classical monocytes and non-classical monocytes characteristics were identified [75]. Nevertheless, GMPs as monocyte precursors were not examined in these studies. It appears that the transcription factor *C/EBP α* acts as an important negative regulator of the *Notch2*-dependent monocyte conversion program. Deletion of *Cebpa* resulted in a decreased Ly6C^{Hi} monocyte pool and facilitated the direct transition of MDPs into non-classical

monocytes. Therefore, absence of *Cebpa* favours the alternative generation of monocytes via the MDP lineage [76]. However, it is unclear, if the remaining Ly6C^{Hi} monocytes observed in *Cebpa*-deficient mice are pro-DC3 (or MDP-derived Ly6C^{Hi} monocytes) or if they are ‘escapees’ that can serve as non-classical monocyte progenitors as observed in *Ccr2*-deficient mice. Other factors involved in *Notch2*-dependent monocyte conversion were identified using this *in vitro* system [77] and comprise activity of IRF2 [75]. The necessity of *Notch2* and *Irf2* for monocyte conversion was verified *in vivo* and mainly endothelial cells in the splenic marginal zone and bone marrow were crucial providers of DLL1 [75, 77]. Moreover, TLR7 activation of classical monocytes was also involved in the conversion to non-classical monocytes in a *Notch2*-independent manner [78]. Other genes that participate in non-classical monocytes generation and maintenance comprise *Nr4a1* [79], *Cebpb* [50, 80], the tyrosine kinase *Lyn* [81], *Cx3cr1-Cx3cl1* [82, 83], and *Bcl6* [75]. Gene deletion of each of these factors leads to the reduction or absence of non-classical monocytes, but the precise genetic interplay between the candidates requires further investigation. The survival of non-classical monocytes depends upon their interaction with the vascular endothelium, mediated through the CX3CL1-CX3CR1 axis, alongside ITGAL (CD11a). This interaction enables the uptake of endothelial-bound CSF1, which is essential for the survival of non-classical monocytes [84]. H-syndrome, a genetic inflammatory disorder that predisposes the patient to histiocytosis, has long puzzled haematologists. This condition is caused by a loss of function mutation in *SLC29A3* that encodes the lysosomal nucleoside transporter ENT3 involved in TLR and MAPK signalling, and results in elevated circulating non-classical monocyte numbers in the blood. Surprisingly, treatment with a MEK inhibitor resolved the histiocytosis, inflammation, and returned the non-classical monocytes back to healthy levels, indicating a crucial role for this lysosomal transporter and MAPK signalling in monocyte homeostasis [85].

Monocyte fluctuation

Transcriptomic and epigenetic analysis of human monocyte subsets showed that classical monocytes express genes involved in the glycolytic and the pentose phosphate pathway, while non-classical monocytes express genes associated with oxidative phosphorylation [86]. Accordingly, constructing and maintaining large quantities of classical monocytes on a daily basis is energy intensive and requires a tight balance to ensure cost-effectiveness to the organism. Indeed, classical monocytes adapt and respond to external disturbances that influence the energy homeostasis of the organism [87]. Quantitative changes in classical monocyte cell numbers could be observed during high-fat diet consumption [65, 88], circadian oscillation [89], ambient temperature [90], and short-term fasting [91], to name a few. Detailed analyses involved in classical monocyte disappearance during fasting indicated at least two possible molecular mechanisms. First, monocyte egression from the bone marrow is inhibited due to reduced systemic CCL2 levels [91]. Second, classical monocytes are quickly drawn back into the bone marrow via the hypothalamic–pituitary–adrenal axis that regulates CXCR4 expression levels on the classical monocyte [68]. These ‘veteran’ cells persist in the bone marrow and are only released once the

energy state is restored. These processes increase the lifespan of classical monocytes and potentially conserve energy that would otherwise be required for the *de novo* generation of a new classical monocyte pool. However, it remains uncertain whether the retracted classical monocytes hinder the generation of new monocytes or if they occupy and obstruct the same cellular niches as newly generated classical monocytes. It is also unclear, how non-classical monocytes respond to these external stimuli, but since non-classical monocytes can adapt their lifespan and accordingly do not rely on a stable and continuous supply of classical monocytes input to maintain their cellular pool [27], it can be speculated that short term classical monocyte fluctuations do not affect more long-lived non-classical monocytes numbers.

Monocyte recruitment

The migratory ability of classical monocytes, coupled with their adaptable chromatin profile, likely grants them considerable flexibility to respond to external factors and adopt diverse phenotypes. This could explain the intricate differentiation potential observed in classical monocytes compared to non-classical monocytes, which remain within their endothelial niche. As such, classical monocytes develop into tissue-resident macrophages in the intestine [72, 92], dermis [93, 94], heart [20, 21], interstitial lung [22–24], and peritoneal/pleural cavities [25]. In addition, during the colonization of a ‘macrophage-free niche’, e.g. after irradiation, diphtheria toxin-mediated depletion of resident macrophages, infection, injury or even ageing, tissue-infiltrated classical monocytes can acquire tissue-resident macrophage phenotypes dictated by the respective tissue microenvironment [95, 96]. This adaptation under homeostatic conditions is almost complete and monocyte-derived macrophages in the tissue are phenotypically indistinguishable from their embryonic counterparts [95, 97]. However, certain transcriptomic and epigenetic differences may persist in monocyte-derived macrophages, which might stem from their distinct cellular origins. Classical monocyte-derived cells originate from adult monocytes, whereas foetal monocytes and EMP (erythro-myeloid progenitors) give rise to embryo-derived macrophages. Although a detailed comparison of the epigenetic landscapes of adult and embryonic monocytic precursors is yet to be conducted, significant transcriptomic differences have been observed between adult and foetal monocytes [98], which might in turn influence the inflammatory response of classical monocyte-derived cells [99, 100]. It is evident that certain genes appear to be exclusively accessible in embryonic-derived macrophages, e.g. *Sall1* in microglia. In contrast, the chromatin structure of these specific genes remains inaccessible to their monocyte-derived counterparts [100–102]. Surprisingly, monocyte-derived microglia that also expressed *Sall1* and were virtually indistinguishable from embryo-derived microglia were recently identified in aged *Ms4a3^{Cre} Rosa26^{LSL-tdTomato} Cx3cr1^{Gfp}* mice [26], indicating that a complete adaptation of monocytes to the unperturbed niche may be possible.

Another explanation for the differences observed between classical monocyte-derived and embryo-derived macrophages lies within the experimental setting itself, which requires the manipulation and removal of macrophages from their niche to allow monocyte colonization. The methods used to create an available empty niche can have severe side effects, for instance, irradiation-induced DNA damage or substantial cell

death in the case of diphtheria toxin-based ablation regimes, which might inadvertently influence the transcriptome of newly recruited monocytes [103].

Building upon the concept that non-classical monocytes may be viewed as terminally differentiated macrophages residing in the blood [27], these monocytes exhibit a reduced tendency to migrate into tissues. Accordingly, non-classical monocytes have only been proposed to differentiate into lung-resident macrophages after adoptive transfer [104]. Additionally, the absence of specialized thymic macrophages in *Nr4a1*-deficient mice correlates with the decrease in non-classical monocyte numbers [105]. However, to confirm if thymic macrophages are bona-fide non-classical monocyte-derived macrophages will require a specific model that targets non-classical monocytes. Instead, non-classical monocytes predominantly remain within the blood, where they are continuously surveying the vasculature by crawling on endothelial cells, which relies on LFA-1/ICAM1 interaction. This process helps to maintain luminal vessel integrity under physiological conditions [106, 107], while during pathology non-classical monocytes participate in the recruitment of neutrophils [106]. Moreover, the functional difference between monocyte subsets also extends to phagocytosis, where non-classical monocytes exhibit an acidic pH within their phagosome, while classical monocytes maintain an alkaline environment [108, 109]. This suggests distinct differences in the mechanisms by which these two subsets process engulfed material. Further investigations into the enzymes released within each phagosome will provide insight into the specific roles these populations play when encountering pathogens.

In summary, classical monocytes show characteristics of an emergency squad that is able to migrate to any tissue and, when a niche becomes available, differentiate under the influence of local tissue-specific factors to tissue-resident macrophages.

Monocyte activation and states

Monocytes and their descendants are often pigeonholed as pro-inflammatory (M1) or anti-inflammatory (M2) in the literature, suggesting that monocytes primarily fulfil one of two functions. Over 30 years ago, the term ‘alternative activation’ was coined, referring to the inherent plastic nature of macrophages when incubated with the Th2 cytokines IL-4 or IL-13 that increases the expression of the mannose receptor. This activation was indeed in contrast to Mackaness’s ‘classical’ microbial activation that results in the production of inflammatory cytokines [110]. Nevertheless, the up-regulation of pro-inflammatory cytokines or nitric oxide synthases (e.g. *Nos2*) compared to steady-state monocytes may not always yield a reliable conclusion with respect to their pro-inflammatory state, and likewise, the expression of genes such as arginase (encoded by *Arg1*) does not always indicate an anti-inflammatory/regulatory function. This oversimplified classification system neglected the nuanced complexity of monocyte biology and overlooks the dynamic changes that occur over time, particularly in the context of pathological processes. For instance, a single monocyte can express both prototypical pro- and anti-inflammatory markers, such as *Arg1* and *Nos2*, while contributing to tissue damage in conditions such as EAE [111, 112]. Furthermore, a detailed analysis of interstitial macrophages demonstrates that

macrophages can respond to the prototypical M1 stimulus IFN γ in a wide variety of activation states that greatly surpass the binary M1 and M2 model [113]. To account for these observations, a spectrum of activation states was proposed, incorporating all intermediate stages between the polarized states from M1 to M2. However, *in vivo* myeloid cells are not only exposed to a variety of cytokine concentrations, but they may also receive a cocktail of various ‘M1’ or ‘M2’ cytokines simultaneously, depending on their local microenvironment and time of infiltration. Analogous to a child (monocyte) in a sweet shop (inflammation) who can not only choose between two specific sweets (e.g. only liquorice or only caramel) but may also experience a wide variety of different flavours, including vanilla, aniseed, mint humbugs, lemon sherbet and chocolate (all synonyms for different cytokines such as IL-10, IL-6, and TNF α ; Fig. 2). As long as an active infection or inflammation is ongoing, monocytes can encounter cyto- and chemokines in close proximity that influence their cellular function and phenotype. Under these circumstances, it is very unlikely that monocytes will only sense IFN γ or IL-4. Rather, monocytes will be exposed and sample other mediators present in a random sequential order depending on the location and time of infiltration. Accordingly, it is possible that monocytes react to TNF α molecules, followed by IL-4, and IFN γ in *immediate succession* (Fig. 2). Therefore, the M1/M2 model may be suitable for *in vitro* experiments, where precise control and supplementation of a single mediator is feasible. However, it fails to mimic the complex 3D structured *in vivo* dynamics and temporal aspects. Accordingly, we respectfully agree with the viewpoint expressed by our colleagues and kindly advocate for the discontinuation of the M1/M2 model (including any spectrum variants), particularly in the context of *in vivo* macrophage biology [114]. We propose a nuanced exploration and description approach of pathologies, such as sterile, helminth, bacterial or viral infections, aiming to elucidate the intricate dynamics of the unique cytokines within each microenvironment and their profound impact on the activation state of monocytes.

Monocyte biology during pathology

Monocytes are migratory cells poised to rapidly reach all regions throughout an organism. Functioning as innate immune sentinels, their primary role is to maintain the organism’s physiological health and homeostasis, during infection in terms of inflammatory activity and during wound healing by tissue remodelling. It is also possible that monocytes seed a growing tissue (like a tumour) to fulfil tissue-resident macrophage functions such as apoptotic cell removal or debris clearance. Therefore, the presence of monocytes in a tissue may suggest that homeostatic balance is yet to be completely restored. The presence of monocytes is therefore not per se detrimental to the tissue. Instead, it raises several questions: Why are monocytes present in a tissue under pathological conditions? What factors are different to the homeostatic situation? How do monocytes contribute to restoring the physiological state?

Our way of life has undergone significant changes over the past two centuries. In the Western world, advancements in medicine have led to an increased life expectancy, although with a higher risk of cancer. Physical activity has declined, a disrupted work/life balance contributes to stress and sleep



Figure 2. The sweet shop analogy. A sweet shop in a village (organism) represents an organ or an inflammatory environment (infection, injury, or tumour). Frequent visitors to the shop are children (monocytes) who have an extraordinary ability to consume many of the sweets, representing cytokines and secreted mediators that are available in the shop. Each shop offers a different selection of sweets, from lollipops and liquorice to marshmallows, where the range of sweets mirrors the cytokines and chemokines found in different inflammatory microenvironments. For instance, liquorice represents pro-inflammatory $\text{TNF}\alpha$, lemon sherbet stands for $\text{IFN}\gamma$, while caramel symbolizes anti-inflammatory IL-4. Yet, there are many other sweets on offer, which can simultaneously be tasted by the children, as long as the shop is open (an indication of ongoing inflammation). Under these circumstances, it is unlikely that the children will only eat caramel (IL-4) or lemon sherbet ($\text{IFN}\gamma$). They will randomly taste other sweets that are available, depending on the architecture of the sweet shop and the sweets on offer. Accordingly, it is possible that the children eat sour lemon sherbet ($\text{IFN}\gamma$), sweet caramel (IL-4), and bitter liquorice ($\text{TNF}\alpha$) in immediate succession, which all influence the mood and behaviour of the children, reflecting gene expression changes and functional adaptation of the monocyte-derived cells. It is also possible that one child does not like the taste of a particular sweet (such as bitter liquorice), symbolizing the absence or down-regulation of certain cyto- or chemokine receptors on monocytes. Therefore, the *in vitro* single stimulus polarization model may be suitable to precisely control the functional outcome of a single mediator. However, it fails to mimic the complex 3D structured *in vivo* dynamics, the many secreted factors available in a microenvironment, temporal aspects of inflammation, and the array of phenotypes monocyte-derived cells can display during different stages of inflammation, injury, or cancer. Drawing by Maya Rachman.

disorders and nutritionally deficient food and beverages are readily available and consumed frequently. The culmination of all these factors influences monocyte biology as mentioned earlier and changes in our lifestyle can contribute or instigate pathological events. For example, in the case of metabolic diseases such as atherosclerosis and obesity, monocytes encounter high concentrations of lipids in arteries or adipose tissue, where a hypoxic environment prevails. As these free or cell-released lipid concentrations exceed the physiological levels, it is possible that monocytes are not equipped with the right molecular machinery or metabolism to perform efficient recycling of the ingested material in the necessary timeframe. The formation of foamy, lipid-laden cells observed under certain metabolic diseases such as atherosclerosis or obesity can point to a restricted catabolic potential that leads

to intracellular lipid (mainly cholesterol) accumulation and compromised macrophage activity. The reason for such a phenotype might be the absence of a gene expression program in macrophages that allows efficient lipid meta- and catabolism due to missing niche-derived instructive signals. The endothelial and adipose niches probably did not evolve to produce cytokines that induce a lipid-handling gene signature in macrophages as observed in the lung, where type II epithelial cells produce CSF2 (also known as GM-CSF) to license surfactant catabolic ability to alveolar macrophages [115, 116] since excessive extracellular lipid accumulation is an unnatural phenomena in vessels and adipose tissue.

In other cases, such as autoimmune neuroinflammation (e.g. multiple sclerosis), it is possible that CNS-infiltrated monocytes receive signals that initiate a context-specific

neurotoxic differentiation program. This inflammatory phenotype might only manifest in the myelin-rich CNS, while the same educated monocytes execute no tissue-destructive activities in other organs [117]. Therefore, the education and environment are equally important to unleash pathogenic functions of monocytes in specific organs. In addition to the prevalent educational milieu, it has also been reported that different concentrations of the same bacterial stimuli (for instance *Staphylococcus aureus*) can evoke distinctive myeloid responses and functions in monocytes [118], which makes it difficult to a priori predict a uniform, standardized immune response of myeloid cells towards a certain pathogen.

Taking all these factors into account, a detailed analysis of the inflammatory context in terms of prevalent cyto- and chemokines, cellular neighbourhood, immunometabolism, pathogen concentration, and cell origin is necessary to define a statement about the potential functionality of monocytes during pathology. We will discuss some of these aspects in the following sections.

The role of monocytes during metabolic diseases

Obesity

Different myeloid cell subsets with distinct functions and origins can be identified in lean and obese adipose tissue. Since this review focuses on monocyte-derived cells under pathological conditions, we refer the reader to two recent, excellent reviews that cover the role of all macrophage subsets during homeostasis and obesity [119, 120]. The first notion that monocyte-derived cells accumulate during obesity in adipose tissue came from bone marrow chimera studies, in which syngeneic CD45.1⁺ bone marrow cells were transferred into irradiated CD45.2⁺ recipients [121]. However, irradiation itself can lead to niche changes and thus influence the results regarding the recruitment of monocytes [122]. When examining the contribution of monocytes to pathology, *Ccr2*-deficient mice have proven an invaluable tool. These mice exhibit reduced circulating classical monocytes, attributed to an egression defect in the bone marrow [123]. Consequently, these mice offer a means to approximate the contribution of classical monocytes to pathogenesis. When *Ccr2*-deficient mice receive a high-fat diet a model of obesity, similar weight gain was observed. However, *Ccr2* deficiency leads to reduced macrophage accumulation in adipose tissue, an attenuated inflammatory milieu, and thereby improved systemic glucose homeostasis and insulin sensitivity [124]. Similar results were observed upon macrophage depletion by clodronate liposomes or in chimeric CD11c^{DTR} mice, which results in decreased accumulation of monocyte-derived cells in adipose tissue [125–127]. Accordingly, the adipose tissue changes reported during obesity were linked to hypertrophy-related hypoxia and the presence of an enriched inflammatory environment [128, 129]. Inflammation indeed contributes to obesity could also be observed in mice with a myeloid-restricted deletion of *Myd88*. These mice showed decreased macrophage recruitment into adipose tissue and were protected from insulin resistance [130]. All these studies led to the hypothesis that the accumulated macrophages are classically activated and that inflammation contributes to tissue damage. The subsequently used term ‘metainflammation’ suggests that pathogen-induced inflammation can be compared to obesity-dependent

inflammation in adipose tissue. Recent research, however, shows that this is not the case. Seminal findings demonstrate that the metabolic activation of macrophages results in a unique macrophage phenotype, which is mechanistically distinct from classical pathogen-induced activation [131]. This indicates that metabolic disease-specific pathways influence macrophage activation likely through discrete mechanisms that differ from those involved in pathogen-dependent activation.

Furthermore, recent transcriptomic analysis of mononuclear phagocytes in adipose tissue revealed a high degree of heterogeneity and proposed distinct functions of each subset during obesity development [119, 132]. These data show in terms of monocyte fate that adipose tissue-infiltrated monocytes mainly develop through a sequential differentiation program into CD9⁺ TREM2⁺ macrophages, also termed lipid-associated macrophages (LAMs [132]); that are located in crown-like structures in proximity to damaged or dying adipocytes [133, 134]. The TREM2-dependent gene program is required to fully differentiate into LAMs and loss of *Trem2* aggravates obesity in terms of adipocyte hypertrophy, body fat accumulation and weight gain [132], although some non-haematopoietic *Trem2*-dependent effects might contribute to this phenotype [135]. Genes involved in the KEGG pathways lysosome, phagosome, and oxidative phosphorylation further characterize LAMs, while inflammatory genes involved in classical activation were not enriched [132]. These results are in contrast to the notion that adipose macrophages acquire a classical pro-inflammatory phenotype under obese conditions and significantly worsen metabolic function as discussed above. Instead, these findings have brought adipose macrophages into the spotlight for therapeutic strategies by targeting directly or indirectly their metabolic activity [132, 136].

Atherosclerosis

Foamy macrophages are a distinctive feature of the atherosclerotic plaque and play an important role in their formation, growth, and potential rupture. *Ccl2* as well as *Ccr2* gene deletion halt the progression of dietary-induced atherosclerosis [137, 138]. Subsequent studies showed that monocytes additionally employ CCR5 and CX₃CR1 receptors to accumulate within lesions and that predominately classical monocytes infiltrate the intima and subintima during atherosclerosis [139]. Recent studies indicate that tissue-resident macrophages in the aortic intima undergo local proliferation. However, in the context of hypercholesterolaemia, these foamy macrophages are replaced by monocyte-derived cells that eventually also adopt a foamy phenotype and gene expression profile similar to those of the previous resident macrophages [140]. Since non-classical monocytes show patrolling behaviour and atherosclerotic lesions affect the arteries, the relevance of these cells during atherogenesis remains under debate. When *Nr4a1*^{-/-} *Apoe*^{-/-} mice—that show reduced numbers of non-classical monocytes—are fed a Western diet, the animals develop aggravated atherosclerosis [141], indicating protective functions of non-classical monocytes. However, *Nr4a1* was also shown to negatively regulate the inflammatory response of classical monocytes [142] and an increased inflammatory profile was evident in the lesions of *Nr4a1*^{-/-} *Apoe*^{-/-} mice [143]. It is therefore possible that once classical monocytes infiltrate into the atherosclerotic plaque they up-regulate

Nr4a1 to limit their activation. The exact contribution of non-classical monocytes requires further investigation, for example mice lacking a specific *Nr4a1* enhancer element that prevents non-classical monocyte generation, but does not limit *Nr4a1* expression under inflammatory conditions [144]. Following the infiltration into lesions, monocyte-derived cells express CD9, genes involved in cholesterol efflux and lipid handling (*Fabp4*, *Trem2*, *Abcg1*), *Lgals3*, *Gpnmb*, *Ctsd*, and *Spp1* [145], which resembles the phenotype of LAMs during obesity. Similar gene expression patterns could be identified in phagocytes isolated from human atherosclerotic vessels [146]. Interestingly, deletion of *Trem2* in myeloid cells reduced plaque deposition and the clinical course of atherosclerosis [147, 148]. These protective effects were attributed to less foamy macrophage generation and reduced survival of plaque macrophages, while systemic inflammation was not affected by *Trem2*-deficiency [147]. Beside lipid-associated cells, macrophages with an inflammatory signature, are evident in mouse and human atherosclerotic plaques [148–150]. Accordingly, deletion of inflammatory genes such as *Myd88*, *Tlr4*, and *Il1b* all diminish plaque formation [151, 152]. As these genetic deletions are not exclusive to monocytes, it remains uncertain which specific subset of macrophages is responsible for mediating the protective effect in atherosclerotic conditions. One could also speculate that circulating lipids may already be impacting the epigenome of blood monocytes, a phenomenon referred to as trained innate immunity [153, 154]. Short-term *in vitro* treatment of monocyte with oxidized low-density lipoprotein (oxLDL) led to enhanced production of TNF α and IL-6, when stimulated 6 days later with TLR2 and TLR4 ligands. Also, the expression of lipid-handling genes (*Cd36*, *Abca1*, *Abcg1*) was increased in these cells, partially due to epigenetic reprogramming [155]. Similarly, hypercholesterolaemia-induced priming of HSC can contribute to atherosclerosis pathology by skewing the haematopoietic output towards the myeloid lineage, thereby aggravating plaque formation in transplanted animals [156].

Further outstanding questions include, how mechanical force in the form of increased shear stress affects macrophage recruitment and function during atherosclerosis [157]. Monocyte infiltration occurs in atherosclerosis-prone areas of the arterial tree where altered fluid hemodynamics prevail, which makes this area particularly prone to protein deposition as observed in the case of tissue-resident intima macrophage-dependent fibrin accumulation [158]. The build-up of cellular dense plaques and increased shear pressure from narrowed arteries might also contribute to the activation of mechanosensitive channels for instance *Piezo1*. PIEZO1 has recently been shown to regulate the inflammatory response of innate immune cells during bacterial infection and fibrotic autoinflammation in the lung [159], and its role in atherosclerosis is currently under investigation [160].

Taken together, the molecular mechanisms of atherosclerotic and adipose macrophages during obesity show similarities, although both subsets occupy discrete cellular niches. Defining commonalities and functional differences, in direct comparison to their circulating monocyte counterparts, will enable a clearer understanding of the function these myeloid cells play during metabolic diseases. In addition, a detailed metabolic analysis of different macrophage populations during obesity-related diseases is necessary to study the metabolic reprogramming of macrophages on a subset level. These results should also consider spatial localization and cellular

communication between different macrophage populations at various time points during pathogenesis to help unravel the therapeutic value of macrophage reprogramming during metabolic diseases.

The role of monocytes during autoinflammatory diseases

Monocytes adopt a prominent role as effector cells and contribute to tissue destruction during autoimmune diseases. The depletion of monocytic cells by either non-specific approaches (e.g. clodronate liposomes, constitutive gene deletion) or specific targeted methods (e.g. Cre-dependent diphtheria toxin depletion) reduce clinical symptoms in various autoinflammatory disease models including arthritis [161], diabetic retinopathy [162], glomerulonephritis [163], or systemic lupus erythematosus [164]. These results indicate that the activation of classical monocytes during autoinflammatory disorders significantly contributes to host tissue damage, which has been extensively studied in the mouse model of multiple sclerosis, EAE, and will be used here as an example of the role of monocytes during autoimmunity. An increase in peripheral classical monocytes has been reported during the pre-clinical phase of EAE [112, 165, 166]. Different depletion systems were used to reduce classical monocyte numbers during the priming phase of the disease or at clinical onset to investigate their contribution to pathology. Only the latter treatment approach significantly improved clinical symptoms and reduced tissue damage in the inflamed CNS [112, 166, 167]. Indeed, classical monocytes were the primary infiltrating cells, which were shown to express *Nos2* and *Arg1* in a sequential manner [168]. A subsequent study confirmed the existence of different monocyte-derived cell stages within the CNS and supported the close relationship between *Nos2*- and *Arg1*-expressing cells [56]. Beside these subsets, also *Cxcl10* expression marked a pathogenic population with a pro-inflammatory signature that do not derive from classical monocytes [56]. Short-term monocyte depletion with an antibody against CCR2 reduced the frequency of these cells in the inflamed CNS and correlated with improved clinical symptoms. These data suggest that *Cxcl10*⁺ cells contribute to the pathogenesis in the short-term depletion EAE experiments.

The establishment of EAE is dependent on cytokines such as CSF2 [169] and IL-6 [170], while gene deletion of TNF α , IFN γ , IL-17, IL-22, and IL-12 did not lead to complete EAE protection [171, 172]. Noteworthy though, deletion of TNF α participated in EAE development by the regulation of monocyte survival [167]. It was shown that monocyte-restricted deletion of the *Csf2* receptor (encoded by *Csf2rb*) renders mice resistant to EAE induction, indicating a crucial role for CSF2 signalling in monocyte-derived cells [173]. scRNA-Seq analysis of *Csf2rb*-deficient monocytes in the CNS of mixed bone marrow chimera revealed a *Csf2*-dependent establishment of *Nos2* and *Arg1* expressing cells, while the development of *Cxcl10*⁺ cells was not affected by *Csf2rb*-deficiency [111]. These data emphasizes that *Nos2*⁺ and *Arg1*⁺ myeloid cells are the main drivers of CSF2-dependent CNS tissue destruction, while *Cxcl10*⁺ cells might contribute to clinical manifestation in another way, possibly in the periphery. This is supported by the fact that *Cxcl10*⁺ monocytes could be detected already in the bone marrow independent of immunization [111]. In summary, these data emphasize that GMP-derived cells in

the CNS during autoimmune neuroinflammation are CSF2-dependent, thereby excluding MDP-derived cells as CSF2-responsive effector cells within the CNS [111].

The significant involvement of monocytes in the initiation of neuroinflammation could also be observed when CSF2 expression was ectopically targeted to T cells. The expression of CSF2 by T cells was sufficient to generate pathogenic monocytes that cause structural damage within the CNS and cause neuropathological symptoms in an antigen-independent manner [117]. The CNS-infiltrated cells in this model showed a distinct lipid-associated gene signature, which emphasized that an efficient monocytic lipid catabolic activity can contribute to tissue damage in a lipid-rich environment like the CNS. Interestingly, the injection of FLT3L into myelin basic protein-CCL2 transgenic mice causes neuroinflammation with predominantly myeloid infiltrates [174]. If FLT3L/CCL2-educated myeloid cells are transcriptionally comparable and mediate tissue damage in a similar fashion to CSF2-educated cells needs to be shown. It also remains to be shown to what extent CSF2-educated monocytes in the transgenic animal model [117] correspond to CNS-infiltrated monocytes from the classical EAE model.

One question that arises regarding monocytes and neuroinflammation remains: How do these CNS-infiltrated monocytes contribute to tissue damage? One obvious answer is that monocytes release reactive oxygen species (ROS) through oxidative burst, perform phagocytosis, and secrete cytokines that exhibit neurotoxic activity. However, the deletion of classical ROS-producing enzymes such as myeloperoxidase (*Mpo*) and *Nos2* does not prevent EAE progression in mice and these genes might even play opposing roles during neuroinflammation [175, 176]. However, all CNS-infiltrated monocyte states and subsets show signs of oxidative stress, characterized by the expression of *Cybb*, *Gpx1*, *Ncf2*, and *Ncf4*, as well as an increased signalling in coagulation and glutathione transferase activity [177]. In addition, *Csf2rb*-dependent cells were enriched in genes involved in inflammasome activation and ROS production, including *Cybb* [111], which might indicate a direct or indirect role for CSF2 in the establishment of oxidative stress response. These pathways possibly lead to the described fibrin deposition and ROS release in EAE lesions that harbour neurotoxic potential. Deletion of *Cybb* in CD11c-expressing cells, which is also expressed in CNS monocyte-derived cells, reduced clinical symptoms during passive EAE [178]. But *Cybb* deletion in *Zbtb46*^{Cre} animals also reduced partially EAE severity [178], indicating a possible role of *Cybb* in cDC rather than monocyte-derived cells.

Another possible mechanism involves the secretion of IL-1 β , which is important for the transmigration of monocytes across the blood-brain barrier and the activation of autoreactive CD4⁺ T cells [179, 180]. The important role of IL-1 β therefore relies on the recruitment of monocytes rather than mediating direct tissue damage.

Taken together, due to their short lifespan and important role in mediating tissue damage, monocytes represent a rational therapeutic target to treat acute relapses of chronic autoimmune diseases.

Monocytes and antigen presentation

Since the initial observation that bone marrow cells cultured with CSF2 or CSF2 complemented with IL-4 acquire a

DC-like phenotype characterized by high CD11c and MHCII expression [181, 182] suggested monocytes participate in antigen presentation. Numerous publications have shown that monocytes can process antigens and accumulate in the inflammatory lesion or in secondary lymphatic organs during inflammatory diseases for a detailed summary in both rodents and humans see [183–185]. Subsequently, different myeloid depletion systems (such as clodronate liposomes [186, 187] or CD11c-dependent DTR mediated depletion system [188]) or the FLT3L-dependence of DC have been used to discriminate the activities of monocyte-derived cells from the cDC lineage, which led to the conclusion that Ly6C-expressing monocytes efficiently participate in T cell polarization and antigen presentation. It was shown that during EAE monocytes can cross-present antigens [189] and that IFN γ signalling is important to drive the MHCII gene signature in CNS monocyte-derived cells [111]. Thus, CCR2-dependent, pre-clinical deletion of MHCII in monocytes reduced neurological symptoms during EAE, thereby emphasizing a critical role for monocytes in T-cell priming [111]. In a model of DSS-induced colitis, transferred monocytes differentiated into colonic *Cx3cr1*-GFP^{int} Ly6C^{low} cells and *Cx3cr1*-GFP^{hi} Ly6C^{low} resident macrophages [190]. *Cx3cr1*-GFP^{int} cells showed expression of *Ccr7*, could be detected in the inflamed colonic lymphatic vasculature, and induced T-cell proliferation *in vitro*.

However, recent advances unravelling myeloid heterogeneity revealed the existence of ‘inflammatory DC2’ and pro-DC3, which both show characteristics of monocytes including expression of Ly6C and CCR2 [23, 191, 192]. Therefore, using Ly6C⁺ CD11b⁺ cells to test the antigen-presenting capacity of monocytes *in vitro* bears the risk of cellular contamination with ‘inflammatory DC2’ and pro-DC3. Purified Ly6C⁺ CD11b⁺ CD115⁺ cells for transfer experiments may contain MDP-derived monocytes or pro-DC3, the latter were shown to harbour antigen presentation capacity and mediate Th17 cell polarizing [23]. Since MDP-derived monocytes showed different migration potential compared to their GMP-derived counterparts [55], it is possible that some of the results mentioned above describe MDP-derived monocytes or pro-DC3 rather than the descendants of classical monocytes. In the future, a careful reevaluation of the existing data that specifically target only classical (GMP-derived) monocytes will help elucidate the specific role of monocytes and antigen-presentation.

Monocytes and the return to healthy homeostasis

Organisms have evolved mechanisms to ensure survival in the face of infection and injury. Regardless the origin of the deleterious stimuli, the fundamental objective of the inflammatory response is to achieve the removal or sequestration of the inciting agent. Inflammation is orchestrated through a series of conserved sequential phases, ultimately leading to tissue remodelling and repair, restoring tissue integrity back to a state of healthy homeostasis. The ‘salutary’ nature of inflammation was recognized over 300 years ago by the father of modern surgery, John Hunter [193]. Wound healing requires the regeneration of damaged cells, while the removal of debris is coordinated by components of the mononuclear phagocyte system. This process is evolutionarily conserved across multicellular organisms and bears a resemblance to developmental biology in certain aspects.

The ongoing discussion in this review regarding the mononuclear phagocyte orchestrators of inflammation, and whether tissue-resident macrophages or blood monocytes are involved in this process, is not a recent quandary. In 1939, Ebert and Florey conducted seminal investigations, tracing the migration of blood monocytes from the circulation to inflammatory sites. Overtime these monocyte-derived cells adopted a morphology reminiscent of macrophages [194] and it was later confirmed that these cells originated in the bone marrow [195, 196]. One exception to this rule occurs in helminth infections, where IL-4 can stimulate the proliferation and the immune activity of resident macrophages independent of recruited monocytes [197]. Nevertheless, in most pathologies, monocyte-derived cells are responsible in the most part in returning tissues back to a healthy state following infection and injury.

The accumulation of cell debris during the inflammatory process ultimately requires its removal in a non-phylogistic fashion [198]. Anti-inflammatory gene expression signatures have been observed in monocyte-derived cells that facilitate tissue regeneration [199–201]. The many faces that infiltrating monocytes may impose throughout the entire inflammatory process, spanning from the genesis to resolution has raised several questions. Do multiple waves of monocyte infiltration occur at distinct phases of the inflammatory response? Or does the same monocyte undertake different functions in a temporal sequence? Trying to answer these questions became even more confusing after the theory of macrophage polarization (M1 and M2) and canonizing the monocyte to an immutable state, as discussed earlier.

Following a skin wound, monocytes and neutrophils enter the site of inflammation almost immediately and represent the first wave of leukocyte immigrants [202]. In injured muscle, heart, intestine, and liver the infiltrating monocyte-derived cells may initially adopt an inflammatory phenotype before helping to restore tissue integrity. Inflammation is a complex process, in turn, monocytes do not simply acquire a binary inflammatory or regulatory phenotype. Instead, the same infiltrating monocyte may respond differently at various stages of the inflammatory process dependent upon the cyto- and chemokines present (Fig. 2). In sterile injury models, such as focussed laser-induced damage to the liver or skeletal muscle injury caused by the tiger snake venom notexin, a myotoxin phospholipase, infiltration of classical monocytes can be observed. Initially, these cells exhibit an inflammatory phenotype and later undergo a transformation into reparative monocytes capable of clearing necrotic debris and orchestrating a return to healthy homeostasis [203, 204]. In the aftermath of skeletal muscle damage, labelled circulating monocytes were shown to migrate to the necrotic site with a pro-inflammatory agenda characterized by high expression of IL-1 β and TNF α . Over time, these infiltrating monocytes clear muscle cell debris and transition into regulatory monocyte-derived cells now expressing IL-10 and TGF- β 1, with the ability to stimulate myogenesis and contributing to the restoration of muscle integrity [203], which emphasizes that the sweets (cytokines) on offer in the shop changed over time (Fig. 2). A similar dynamic behaviour could be observed in tissue-infiltrated monocytes after myocardial infarction. During the initial state, monocytes exhibit elevated levels of IL-1 β , TNF α , and protease activity to facilitate the breakdown of the extracellular matrix. Subsequently,

these monocyte-derived cells contribute to tissue remodelling and repair by expressing IL-10, TGF- β 1, and VEGF, thereby promoting neoangiogenesis and myofibroblast accumulation [205]. This regulatory behaviour is contingent on the transcription factor NR4A1 [142]. Also following retinal injury, monocyte-derived cells release IL-10 and contribute significantly to the survival and proliferation of retinal progenitor cells for the restoration of homeostasis [206].

The function of monocytes during inflammation and resolution is not only dependent on instructive cyto- and chemokines but also on the concentration of the inflammatory stimulus itself. In a model of skin infection with a high dose of *Staphylococcus aureus*, classical monocyte infiltration is reduced, while neutrophils dominate the inflammatory lesion [118]. In contrast, a low dose of *Staphylococcus aureus* infection led to equal infiltration of classical monocytes and neutrophils. Importantly though, monocytes did not enter the lesion core or contribute to bacteria elimination but rather facilitated neovascularization during the post-infection resolution phase of tissue remodelling [118]. This process was mediated by ghrelin which modulates adipocyte leptin levels, leading to a reduction in vascular overgrowth and promoting efficient wound repair. In the absence of monocytes, a collagenous scar develops and becomes highly vascularized, underscoring the essential role played by monocytes in restoring injured tissue to a state of healthy homeostasis.

The balance between wound healing and fibrosis is a fine tightrope that can be observed in cases of paracetamol-induced liver injury. Infiltrating monocyte-derived cells play a crucial role in hepatic regeneration and the clearance of neutrophils [207, 208]. This was also observed in carbon tetrachloride-induced liver fibrosis, where classical monocytes are recruited to the fibrotic liver and contribute to resolving tissue fibrosis. Their actions involve degrading the extracellular matrix, clearing cellular debris, and expediting scar resolution [200].

These examples show that monocytes have the ability to change from a pro-inflammatory to a regulatory phenotype in response to changes in the microenvironment during distinct phases of the immune response. Circulating monocytes also adopt a regulatory phenotype not only before arriving at the site of inflammation but can be reprogrammed already in the bone marrow. In an oral infection model of *Toxoplasma gondii*, DC in the mesenteric lymph node produces IL-12 that acts in a systemic manner to activate NK cells in the bone marrow, leading to an increase in local IFN γ production. This IFN γ then reprograms monocytes by downregulating the chemokine receptor CX $_3$ CR1, prompting them to express Sca1 $^+$, and produce IL-10 and PGE $_2$. This immunological circuit ultimately results in regulatory monocytes that prevent lethal pathology by modulating tissue-specific immunity in the gut [209]. In another cellular circuit, monocytes recruited to allergically inflamed skin undergo differentiation to mitigate the allergic response in the presence of basophil-derived IL-4 [210].

These investigations emphasize the plasticity of monocyte-derived cells during the inflammatory response and demonstrate their capacity to undergo a phenotype switch that facilitates the return to a state of healthy homeostasis. At every phase of the immune response, the monocyte-derived cell functions are influenced by its microenvironment, enabling the recovery process. By capitalizing on certain

beneficial aspects of the regulatory monocyte-derived cells, we could counter chronic inflammation and facilitate a return to a steady state.

The role of monocytes in cancer development

At least at the initial stages, solid tumours can be perceived as a newly developing organ [211] that relies on apoptotic cell removal, clearance of cellular debris, angiogenesis, immunosuppression, and remodelling of the extracellular matrix. Tumour macrophages are engaged in all these tasks and the roles adopted by mononuclear phagocytes in solid tumours are therefore analogous to their physiological role in organ development during embryogenesis. Accordingly, tumour macrophages are central contributors to cancer biology.

The solid tumour harbours distinct populations of mononuclear phagocytes that either promote or suppress cancer progression depending on the tumour stage, location, immunogenicity and microenvironment. Both classical monocytes and tissue-resident macrophages have the capacity to transform into tumour-associated macrophages (TAMs) throughout the course of tumour development. The literature commonly refers to both these populations as TAM irrespective of their origin. However, it is possible that each neighbourhood within the tumour dictates a discrete function of the TAM population, as previously described in breast cancer [212]. Monocyte-derived (mo)TAM (for example TREM2⁺ TAM) infiltrate the tumour core, whereas tissue-resident-derived TAMs (such as FOLR2⁺ TAM) are predominately located within the perivascular niche of the tumour stroma [212]. These spatial differences likely result in a different microenvironment and may account for the observed functional differences: while FOLR2⁺ TAMs are strategically positioned to interact with T cells and are accordingly involved in mounting a possible adaptive immune response against the tumour by priming CD8⁺ T cells [212], moTAMs are in direct contact with (apoptotic) tumour cells and experience a hypoxic environment. The clearance of tumour debris and direct signals from tumour cells can contribute to a lipid-associated gene signature and the immunosuppressive state of moTAMs [213]. However, CCR2-dependent moTAMs can also exhibit immune responses by the upregulation of antigen presentation machinery and the release of inflammatory cytokines in T cell-rich pancreatic ductal adenocarcinoma (PDAC) in patients and murine PDAC models, whereas embryonically derived macrophages exhibit a profibrotic signature that contribute to the remodelling of the tumour microenvironment (TME) [214]. In this model, the differentiation of moTAM has recently been shown to follow several stages; initially the infiltrated cells adopt a transient transcriptional profile characterized by *Tnf* and *Ccr2* expression. This population can then further differentiate into two distinct TAM populations, one characterized by *Hif1a* expression and an hypoxic phenotype, while the other shows an immunomodulatory phenotype accompanied by *Trem2* expression. Which differentiation pathway is adopted by the cells is apparently dictated by the microenvironment of the tumour [215]. Indeed, when PDAC monocytes interact with tumour-specific CD4⁺ T cells they can acquire an anti-tumourigenic MHCII^{hi} phenotype, while in the absence of direct lymphocyte contact, tumour-infiltrated monocytes follow the default differentiation into FOLR2⁺ TAMs, promoting tumour growth [216]. The interplay between myeloid cells

and T cells has the potential to promote an ‘anti-tumour’ macrophage response, which may be independent of ontogeny. In contrast, in the absence of such signals, macrophages adopt a default TAM phenotype that supports tumour growth in non-immunogenic cancers.

These examples illustrate the intricate interplay between monocytes with their tumour surroundings and how this influences the function of TAMs. Factors including the rate of cell death, immunogenicity, tissue specificity, localization, immune cell infiltrates, grade of hypoxia, local tumour-derived chemo- and cytokines, macrophage ontogeny, and time all contribute to the heterogeneity of TAMs in different tumours. A detailed understanding of these factors will help to predict TAM functions and may be therapeutically valuable to influence TAM differentiation to favour an immune activation phenotype over an immune suppressive state. Permitting other immune cells like T cells access to the tumour core and thereby allowing them to interact with TAM could further help to modulate and increase the immunosuppression state of moTAM.

Maintaining an optimal oxygen concentration is crucial for tissue survival. Tumour hypoxia emerges out of uncontrolled cell proliferation in combination with restricted blood vessel formation, which limits the supply of oxygen. This hypoxic environment prompts responses such as angiogenesis. In the face of hypoxia, recruited monocytes can be activated to participate in angiogenesis, while the hypoxic milieu induces various phenotypic changes. A population of monocytes that express Tie2⁺ has been described as pro-angiogenic [217]. Tie2 appears to be expressed on human intermediate/non-classical human monocytes and is significantly increased in patients with non-small cell lung cancer [218, 219]. However, in a mouse model of angiogenesis, infiltrating classical monocytes undergo transformative changes, acquiring the ability to remodel and generate blood vessels and down-regulate their classical phenotype. Notably, these monocytes appear transient at the angiogenic site and are constantly replenished [220]. In response to low oxygen levels, monocytes up-regulate hypoxia-inducible transcription factors, particularly HIF1 α and HIF2 α . The myeloid-specific deletion of HIF1 α in the murine MMTV-PyMT model reduced tumour growth [221]. Similarly, the absence of HIF2 α in TAM showed positive outcomes in hepatocellular and colitis-associated colon carcinomas, associated with a reduced monocyte migration to the tumour [222]. The infiltration of Tie2⁺ VEGFR⁺ CD11b⁺ F4/80⁺ cells in an orthotopic mouse model of glioblastoma occurs also in a HIF1 α -dependent manner. These monocyte-derived cells secrete matrix metalloproteinase 9 (MMP9), sufficient to activate the bioavailability of VEGF and turn the angiogenic switch [223]. However, the role of monocytes in facilitating angiogenesis during tumour formation requires further investigation.

Heterogeneity and roles of monocyte-derived TAMs in tumour progression

A comprehensive profiling of myeloid cells isolated from 15 distinct cancer types indicated that TAM are more heterogeneous across each cancer type in comparison to circulating monocytes from the same patients [224], indicating the local TME most likely influences the phenotype of TAM in a complex fashion, similar to the tissue-imprinting of resident

macrophages by the organs [97]. Nevertheless, comprehensive scRNA-Seq analysis from different human cancer types was able to classify the possible moTAM populations into two groups: SPP1⁺ macrophages and C1QC⁺ macrophages. Functionally, these two macrophage populations appear to be mutually exclusive [224].

SPP1⁺ macrophages highly upregulate *Vegfa*, *Marco*, *Mmp12* genes and express the transcription factors *Cebpb* and *Bhlhe40*. Pathway analysis indicated SPP1⁺ macrophages are associated with tumour angiogenesis, phagocytosis, lipid metabolism, and ECM interactions including the upregulation of metalloproteases [225]. Indeed, they actively interact with cancer-associated fibroblasts or myofibroblast [226]. High expression of *SPP1* correlates with a worse clinical outcome in several cancer types [225] and accordingly SPP1⁺ macrophages are thought to support tumour progression as tumorigenic macrophages.

While C1QC⁺ macrophages significantly increased genes related to phagocytosis compared to SPP1⁺ macrophages [224]. In patients with CRC, RNA velocity analysis of scRNA-Seq data inferred that CD14⁺ monocytes transit to FCN1⁺ monocyte-derived cells, which finally differentiate into C1QC⁺ macrophage subsets [225]. In this study, pathway analysis revealed that C1QC⁺ macrophages show enhanced complement activation and antigen processing/presentation capacity, which emphasizes that they interact with T-cell subsets in patients with CRC. Especially, ligand-receptor pairing analysis of scRNA-Seq showed the enrichment of CXCL10-CXCR3 interaction in C1QC⁺ macrophages, indicating that C1QC⁺ macrophages are involved in T-mediated tumour suppression.

However, in addition to SPP1⁺ and C1QC⁺ TAM populations, tumour-infiltrating monocytes have been identified and described as other cancer-specific moTAM subsets including TREM2⁺ TAM and IL-1 β ⁺ TAM. TREM2⁺ TAMs were initially identified by scRNA-Seq in early lung adenocarcinoma patients [227] and can even be detected at the preclinical stage [228]. These cells further express *CD63*, *SPP1*, and *MARCO* and the presence of this gene signature negatively correlated with patients' survival, indicating that TREM2⁺ TAMs play a similar to SPP1⁺ TAM a pro-tumorigenic and/or immunosuppressive role. Subsequent research showed that the uptake of tumour debris induced the TREM2 gene program in mouse monocyte-derived macrophages (including *Trem2*, *Lpl*, *Cd274*, and *ApoE*), while non-phagocytic cells are immunogenic [213]. Genetic deletion of *Trem2* or therapeutic blockade by anti-TREM2 antibody administration reduced tumour growth in mainly transplantable cancer models [213, 229–231]. In the absence of *Trem2*, TAM in primary lung adenocarcinoma were unable to express IL18bp, which normally intercepts IL-18 and prevents IL-18-dependent activation of NK cells [213]. Accordingly, NK cells show higher anti-tumorigenic activity in *Trem2*-deficient mice. Anti-TREM2 antibody administration during a GL261-induced mouse glioblastoma model also prevents the formation of classical TREM2⁺ TAM and redirects their transcriptomic signature towards pro-inflammatory states [230]. The effectiveness of TREM2 blockade in these models suggests that TREM2⁺ TAM plays a widespread functional role during tumorigenesis, and indeed TREM2⁺ TAM could be detected in a large number of different human carcinoma types, including lung, colon, liver, breast, stomach, and pancreas datasets [231, 232].

Trajectory analysis showed that IL-1 β ⁺ TAM originates from circulating monocytes and are induced by prostaglandin E₂ (PGE₂) secreted by tumour cells in PDAC patients and mice [233]. This loop between IL-1 β ⁺ TAMs and PDAC shapes the tumour-intrinsic IL-1 β response program in hypoxic regions of the pancreatic tumours, resulting in early tumorigenesis. As IL-1 β is also highly expressed in PDAC tumour cells [234] and other cancer-associated stromal cells in pancreatic cancer [235, 236], it is possible that PDAC-derived IL-1 β can directly induce the proliferation of neighbouring cancer stem cells, resulting in tumour growth. To clearly define whether IL-1 β ⁺ TAMs are involved in promoting tumours, tumour growth could be assessed in the orthotopic model using IL-1 β KO PDCA cell lines or IL-1 β depletion in monocyte-derived macrophage models.

It is currently unclear, how and if TREM2⁺, SPP1⁺, C1QC⁺, and IL-1 β ⁺ TAM are related or if they describe specific cellular states that depend on pathogenesis and tissue localization. Some literature reports describe an overlapping transcriptomic signature of TREM2⁺ with SPP1⁺ [212], or C1QC⁺ TAM [225] and thereby suggest that some of the markers might describe the same TAM subsets. Recently, *Spp1*-GFP knock-in mice and *Spp1*-CreER mice were generated [237]. These animals are a valuable addition to help reveal the role and fate of SPP1⁺ TAM during tumour progression. In addition, the strong lipid-associated gene pattern observed in TREM2⁺ and SPP1⁺ TAMs suggests that both subsets acquire a phenotype with similar pro-tumorigenic function. An unbiased meta-analysis incorporating all these datasets and establishing a standardized nomenclature will help streamline the categorization and function of the different TAM subsets preventing redundancy and enhancing data set accessibility. This in turn will hopefully aid the development of specific tailored treatments.

Conclusion

The notion of 'the monocyte' has altered considerably over the past 30 years, from a homogeneous population of circulating leukocytes dedicated to macrophage repopulation, to a heterogeneous population with a diverse functional repertoire. Recent data suggest that monocyte heterogeneity is already evident at their progenitor level as mouse classical monocytes might emerge via two alternative developmental routes: one differentiation passes through the GMP-cMoP axis, while the other differentiates through MDP. However, it is currently unclear, if both subsets belong to the monocyte lineage or if MDP-derived cells show characteristics of DC. Nevertheless, monocytes are much more than macrophage progenitor cells. Circulating monocytes fulfil a crucial role as a rapid-response unit, orchestrating the initiation and resolution phases of infection, wounds, and disease. These diverse roles share one goal: to restore the physiological balance and a return to tissue equilibrium. Furthermore, monocyte-derived cells can also perform functions that tissue-resident macrophages or DC cannot, although some similarities may occur. Under specific conditions such as spinal cord injury, monocyte-derived cells are able to participate in IL-10-dependent wound healing, while microglia that share the same environment are unable to fulfil these functions [238]. This example demonstrates that the origin-dependent epigenetic imprinting of monocyte permits functions that complement the functions

of tissue-resident cells. Yet monocytes are unable to discriminate tumourigenic cells from healthy cells and they can also be easily misled by lymphocytes to mount an overzealous immune response resulting in tissue destruction, as evident in autoinflammatory diseases. Understanding the causes of monocyte infiltration in conjunction with their surrounding microenvironment will aid design future therapeutics that either block or enhance certain monocytic functions. Furthermore, since monocytes are constantly replenished and do not bear a long-lasting genetic immunological memory, the manipulation of circulating monocyte numbers either by their specific depletion, by therapeutics or via specific behaviour such as intermittent fasting, represents an attractive clinical intervention strategy for many acute diseases. Since monocytes can efficiently infiltrate tissues under pathological conditions, they may also be exploited and used therapeutically as ‘Trojan horses’. Accordingly, *ex vivo* manipulation of monocytes might be a suitable approach to equip monocytes with new functions that can beneficially influence the cytokine or cellular milieu of the pathological lesion.

Acknowledgments

A.M. is supported by the Research Council of Finland’s Flagship InFLAMES (337530 and 357910), the German Research Foundation (SPP2395; MI1328), the Jane and Aatos Erkko Foundation, the Sigrid Juselius Foundation, and the Research Council of Finland (355727). SY is supported by the Israel Science Foundation (192/20). K-W.K. is supported by National Institute of Health grant R01DK126753. We would like to thank Maya Rachman for drawing Fig. 2. We apologise to our peers if we overlooked any studies in this review due to our ignorance.

Author contributions

Alexander Mildner (Writing—original draft), Ki-Wook Kim (Writing—original draft), and Simon Yona (Writing—original draft)

Conflict of interest

The authors declare that they have no conflict of interest. A.M., K.W.K., and S.Y. wrote the manuscript.

Data availability

No new data were generated in support of this review.

References

- Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. *Nat Rev Immunol* 2014, **14**, 571–8. doi:10.1038/nri3712
- van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort HL. [Mononuclear phagocytic system: new classification of macrophages, monocytes and of their cell line]. *Bull World Health Organ* 1972, **47**, 651–8.
- Yona S, Gordon S. From the reticuloendothelial to mononuclear phagocyte system - the unaccounted years. *Front Immunol* 2015, **6**, 328. doi:10.3389/fimmu.2015.00328
- Pappenheim A, Ferrata A. Über die verschiedenen lymphoiden Zellformen des normalen und pathologischen Blutes. *Folia haemat.* 1910, **10**, 72–208.
- Ehrlich P. Methodologische Beiträge zur Physiologie und Pathologie der verschiedenen Formen der Leukocyten. *Zeitschrift fuer klinische Medizin* 1880, **1**, 553–60.
- Forkner CE. The origin of monocytes in certain lymph nodes and their genetic relation to other connective tissue cells. *J Exp Med* 1930, **52**, 385–404. doi:10.1084/jem.52.3.385
- Klein S, *Die Myeloblasten und die Übergangszellen Ehrlichs*. In: *Die Myelogenie*. Berlin, Heidelberg: Springer, 1914.
- Naegeli O, *Blutkrankheiten und Blutdiagnostik: Lehrbuch der Klinischen Hämatologie*. Berlin: Springer, 1923.
- Sabin FR, Doan CA, Cunningham RS. Discrimination of two types of phagocytic cells in the connective tissues by the supravital technique. *Contrib Embryol* 1925, **16**, 125–62.
- Ziegler-Heitbrock L. Monocyte subsets in man and other species. *Cell Immunol* 2014, **289**, 135–9. doi:10.1016/j.cellimm.2014.03.019
- Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. *Blood* 1989, **74**, 2527–34.
- Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity* 2003, **19**, 71–82. doi:10.1016/s1074-7613(03)00174-2
- Palframan RT, Jung S, Cheng G, Weninger W, Luo Y, Dorf M, et al. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. *J Exp Med* 2001, **194**, 1361–73. doi:10.1084/jem.194.9.1361
- Jakubzick C, Gautier EL, Gibbins SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. *Immunity* 2013, **39**, 599–610. doi:10.1016/j.immuni.2013.08.007
- Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol Cell Biol* 2000, **20**, 4106–14. doi:10.1128/MCB.20.11.4106-4114.2000
- Meghraoui-Kheddar A, Barthelemy S, Boissonnas A, Combadière C. Revising CX3CR1 expression on murine classical and non-classical monocytes. *Front Immunol* 2020, **11**, 1117. doi:10.3389/fimmu.2020.01117
- Sommer K, Garibagaoglu H, Paap E-M, Wiendl M, Müller TM, Atraya I, et al. Discrepant phenotyping of monocytes based on CX3CR1 and CCR2 using fluorescent reporters and antibodies. *Cells* 2024, **13**, 819. doi:10.3390/cells13100819
- Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H, et al. Intestinal lamina propria dendritic cell subsets have different origin and functions. *Immunity* 2009, **31**, 502–12. doi:10.1016/j.immuni.2009.06.025
- Bain CC, Mowat AM. The monocyte-macrophage axis in the intestine. *Cell Immunol* 2014, **291**, 41–48. doi:10.1016/j.cellimm.2014.03.012
- Molawi K, Wolf Y, Kandalla PK, Favret J, Hagemeyer N, Frenzel K, et al. Progressive replacement of embryo-derived cardiac macrophages with age. *J Exp Med* 2014, **211**, 2151–8. doi:10.1084/jem.20140639
- Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity* 2014, **40**, 91–104. doi:10.1016/j.immuni.2013.11.019
- Chakarov S, Lim HY, Tan L, Lim SY, See P, Lum J, et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. *Science* 2019, **363**, eaau0964. doi:10.1126/science.aau0964
- Liu Z, Wang H, Li Z, Dress RJ, Zhu Y, Zhang S, et al. Dendritic cell type 3 arises from Ly6C(+) monocyte-dendritic cell progenitors. *Immunity* 2023, **56**, 1761–77.e6. doi:10.1016/j.immuni.2023.07.001
- Neehus AL, Carey B, Landkic M, Panikulam P, Deutsch G, Ogishi M, et al. Human inherited CCR2 deficiency underlies

- progressive polycystic lung disease. *Cell* 2024, **187**, 3460–408 e23. doi:[10.1016/j.cell.2024.05.021](https://doi.org/10.1016/j.cell.2024.05.021)
25. Kim KW, Williams JW, Wang Y-T, Ivanov S, Gilfillan S, Colonna M, et al. MHC II+ resident peritoneal and pleural macrophages rely on IRF4 for development from circulating monocytes. *J Exp Med* 2016, **213**, 1951–9. doi:[10.1084/jem.20160486](https://doi.org/10.1084/jem.20160486)
 26. Kim J-S, Trzebanski S, Shin S-H, Ilani NC, Kaushansky N, Scheller M, et al. Monocyte-derived microglia with Dnmt3a mutation cause motor pathology in aging mice. *bioRxiv* 2023, 2023.11.16.567402.
 27. Yona S, Kim K-W, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 2013, **38**, 79–91. doi:[10.1016/j.immuni.2012.12.001](https://doi.org/10.1016/j.immuni.2012.12.001)
 28. Kanitakis J, Petruzzo P, Dubernard JM. Turnover of epidermal Langerhans' cells. *N Engl J Med* 2004, **351**, 2661–2. doi:[10.1056/NEJM200412163512523](https://doi.org/10.1056/NEJM200412163512523)
 29. Mielcarek M, Kirkorian AY, Hackman RC, Price J, Storer BE, Wood BL, et al. Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation. *Transplantation* 2014, **98**, 563–8. doi:[10.1097/TP.000000000000097](https://doi.org/10.1097/TP.000000000000097)
 30. Collin MP, Hart DNJ, Jackson GH, Cook G, Cavet J, Mackinnon S, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. *J Exp Med* 2006, **203**, 27–33. doi:[10.1084/jem.20051787](https://doi.org/10.1084/jem.20051787)
 31. Volc-Platzer B, Stingl G, Wolff K, Hinterberg W, Schnedl W. Cytogenetic identification of allogeneic epidermal Langerhans cells in a bone-marrow-graft recipient. *N Engl J Med* 1984, **310**, 1123–4. doi:[10.1056/NEJM198404263101721](https://doi.org/10.1056/NEJM198404263101721)
 32. Maximow A. über die Entwicklung der Blut-und Bindegewebszellen beim Säugetier-embryo. *Folia Haematologica* 1907, **4**, 611–26.
 33. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 1961, **14**, 213–22.
 34. Osawa M, Nakamura K, Nishi N, Takahashi N, Tokuomoto Y, Inoue H, et al. In vivo self-renewal of c-Kit+ Sca-1+ Lin(low/-) hemopoietic stem cells. *J Immunol* 1996, **156**, 3207–14.
 35. Schoedel KB, Morcos MNE, Zerjatke T, Roeder I, Grinenko T, Voehringer D, et al. The bulk of the hematopoietic stem cell population is dispensable for murine steady-state and stress hematopoiesis. *Blood* 2016, **128**, 2285–96. doi:[10.1182/blood-2016-03-706010](https://doi.org/10.1182/blood-2016-03-706010)
 36. Busch K, Klapproth K, Barile M, Flossdorf M, Holland-Letz T, Schlenner SM, et al. Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. *Nature* 2015, **518**, 542–6. doi:[10.1038/nature14242](https://doi.org/10.1038/nature14242)
 37. Sheikh BN, Yang Y, Schreuder J, Nilsson SK, Bilardi R, Carotta S, et al. MOZ (KAT6A) is essential for the maintenance of classically defined adult hematopoietic stem cells. *Blood* 2016, **128**, 2307–18. doi:[10.1182/blood-2015-10-676072](https://doi.org/10.1182/blood-2015-10-676072)
 38. Williams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. *Immunity* 2018, **49**, 595–613. doi:[10.1016/j.immuni.2018.10.005](https://doi.org/10.1016/j.immuni.2018.10.005)
 39. Pietras EM, Reynaud D, Kang Y-A, Carlin D, Calero-Nieto FJ, Leavitt AD, et al. Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. *Cell Stem Cell* 2015, **17**, 35–46. doi:[10.1016/j.stem.2015.05.003](https://doi.org/10.1016/j.stem.2015.05.003)
 40. Grinenko T, Eugster A, Thielecke L, Ramasz B, Krüger A, Dietz S, et al. Hematopoietic stem cells can differentiate into restricted myeloid progenitors before cell division in mice. *Nat Commun* 2018, **9**, 1898. doi:[10.1038/s41467-018-04188-7](https://doi.org/10.1038/s41467-018-04188-7)
 41. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. *Nature* 2000, **404**, 193–7. doi:[10.1038/35004599](https://doi.org/10.1038/35004599)
 42. Lee J, Breton G, Oliveira TYK, Zhou YJ, Aljoufi A, Pühr S, et al. Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. *J Exp Med* 2015, **212**, 385–99. doi:[10.1084/jem.20141442](https://doi.org/10.1084/jem.20141442)
 43. Fogg DK, Sibon C, Miled C, Jung S, Aucouturier P, Littman DR, et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. *Science* 2006, **311**, 83–7. doi:[10.1126/science.1117729](https://doi.org/10.1126/science.1117729)
 44. Olsson A, Venkatasubramanian M, Chaudhri VK, Aronow BJ, Salomonis N, Singh H, et al. Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. *Nature* 2016, **537**, 698–702. doi:[10.1038/nature19348](https://doi.org/10.1038/nature19348)
 45. Sathe P, Metcalf D, Vremec D, Naik SH, Langdon WY, Huntington ND, et al. Lymphoid tissue and plasmacytoid dendritic cells and macrophages do not share a common macrophage-dendritic cell-restricted progenitor. *Immunity* 2014, **41**, 104–15. doi:[10.1016/j.immuni.2014.05.020](https://doi.org/10.1016/j.immuni.2014.05.020)
 46. Hettlinger J, Richards DM, Hansson J, Barra MM, Joschko A-C, Krijgsveld J, et al. Origin of monocytes and macrophages in a committed progenitor. *Nat Immunol* 2013, **14**, 821–30. doi:[10.1038/ni.2638](https://doi.org/10.1038/ni.2638)
 47. Paul F, Arkin Y'ara, Giladi A, Jaitin DA, Kenigsberg E, Keren-Shaul H, et al. Transcriptional heterogeneity and lineage commitment in myeloid progenitors. *Cell* 2015, **163**, 1663–77. doi:[10.1016/j.cell.2015.11.013](https://doi.org/10.1016/j.cell.2015.11.013)
 48. Yanez A, Coetzee SG, Olsson A, Muench DE, Berman BP, Hazelett DJ, et al. Granulocyte-monocyte progenitors and monocyte-dendritic cell progenitors independently produce functionally distinct monocytes. *Immunity* 2017, **47**, 890–902.e4. doi:[10.1016/j.immuni.2017.10.021](https://doi.org/10.1016/j.immuni.2017.10.021)
 49. Weinreb C, Rodriguez-Fraticelli A, Camargo FD, Klein AM. Lineage tracing on transcriptional landscapes links state to fate during differentiation. *Science* 2020, **367**, eaaw3381. doi:[10.1126/science.aaw3381](https://doi.org/10.1126/science.aaw3381)
 50. Mildner A, Schönheit J, Giladi A, David E, Lara-Astiaso D, Lorenzo-Vivas E, et al. Genomic characterization of murine monocytes reveals C/EBPbeta transcription factor dependence of Ly6C- cells. *Immunity* 2017, **46**, 849–62.e7. doi:[10.1016/j.immuni.2017.04.018](https://doi.org/10.1016/j.immuni.2017.04.018)
 51. Menezes S, Melandri D, Anselmi G, Perchet T, Loschko J, Dubrot J, et al. The heterogeneity of Ly6Chi monocytes controls their differentiation into iNOS+ macrophages or monocyte-derived dendritic cells. *Immunity* 2016, **45**, 1205–18. doi:[10.1016/j.immuni.2016.12.001](https://doi.org/10.1016/j.immuni.2016.12.001)
 52. Liu Z, Gu Y, Chakarov S, Bleriot C, Kwok I, Chen X, et al. Fate mapping via Ms4a3-expression history traces monocyte-derived cells. *Cell* 2019, **178**, 1509–25.e19. doi:[10.1016/j.cell.2019.08.009](https://doi.org/10.1016/j.cell.2019.08.009)
 53. Liu K, Victoria GD, Schwickert TA, Guermontprez P, Meredith MM, Yao K, et al. In vivo analysis of dendritic cell development and homeostasis. *Science* 2009, **324**, 392–7. doi:[10.1126/science.1170540](https://doi.org/10.1126/science.1170540)
 54. Kamio N, Yokota A, Tokuda Y, Ogasawara C, Nakano M, Nagao M, et al. A novel CD135(+) subset of mouse monocytes with a distinct differentiation pathway and antigen-presenting properties. *J Immunol* 2022, **209**, 498–509. doi:[10.4049/jimmunol.2100024](https://doi.org/10.4049/jimmunol.2100024)
 55. Trzebanski S, Kim J-S, Larossi N, Raanan A, Kancheva D, Bastos J, et al. Classical monocyte ontogeny dictates their functions and fates as tissue macrophages. *Immunity* 2024, **57**, 1710–2. doi:[10.1016/j.immuni.2024.06.011](https://doi.org/10.1016/j.immuni.2024.06.011)
 56. Giladi A, Wagner LK, Li H, Dörr D, Medaglia C, Paul F, et al. Cxcl10(+) monocytes define a pathogenic subset in the central nervous system during autoimmune neuroinflammation. *Nat Immunol* 2020, **21**, 525–34. doi:[10.1038/s41590-020-0661-1](https://doi.org/10.1038/s41590-020-0661-1)
 57. Cytlak U, Resteu A, Pagan S, Green K, Milne P, Maisuria S, et al. Differential IRF8 transcription factor requirement defines two pathways of dendritic cell development in humans. *Immunity* 2020, **53**, 353–70.e8. doi:[10.1016/j.immuni.2020.07.003](https://doi.org/10.1016/j.immuni.2020.07.003)
 58. Dutertre CA, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. *Immunity* 2019, **51**, 573–89. doi:[10.1016/j.immuni.2019.08.008](https://doi.org/10.1016/j.immuni.2019.08.008)

59. Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, et al. Transcriptional and functional analysis of CD1c(+) human dendritic cells identifies a CD163(+) subset priming CD8(+) CD103(+) T cells. *Immunity* 2020, 53, 335–52.e8. doi:10.1016/j.immuni.2020.06.002
60. Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. *Science* 2017, 356. doi:10.1126/science.aah4573
61. Lubin R, Gvili R, Hazan I, Yona S. Human dendritic cell enrichment and their activation of T cells. *Curr Protoc* 2023, 3, e873. doi:10.1002/cpz1.873
62. Emoto T, Lu J, Sivasubramaniam T, Maan H, Khan AB, Abow AA, et al. Colony stimulating factor-1 producing endothelial cells and mesenchymal stromal cells maintain monocytes within a perivascular bone marrow niche. *Immunity* 2022, 55, 862–78.e8. doi:10.1016/j.immuni.2022.04.005
63. Momenilandi M, Lévy R, Sobrino S, Li J, Lagresle-Peyrou C, Esmailzadeh H, et al. FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. *Cell* 2024, 187, 2817–37.e31. doi:10.1016/j.cell.2024.04.009
64. Chong SZ, Evrard M, Devi S, Chen J, Lim JY, See P, et al. CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses. *J Exp Med* 2016, 213, 2293–314. doi:10.1084/jem.20160800
65. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. *J Clin Invest* 2007, 117, 902–9. doi:10.1172/JCI29919
66. Jung H, Mithal DS, Park JE, Miller RJ. Localized CCR2 activation in the bone marrow niche mobilizes monocytes by desensitizing CXCR4. *PLoS One* 2015, 10, e0128387. doi:10.1371/journal.pone.0128387
67. Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. *Immunity* 2011, 34, 590–601. doi:10.1016/j.immuni.2011.02.016
68. Janssen H, Kahles F, Liu D, Downey J, Koekkoek LL, Roudko V, et al. Monocytes re-enter the bone marrow during fasting and alter the host response to infection. *Immunity* 2023, 56, 783–96.e7. doi:10.1016/j.immuni.2023.01.024
69. Debieu E, Mayol K, Biaisoux V, Daussy C, De Agüero MG, Taillardat M, et al. S1PR5 is pivotal for the homeostasis of patrolling monocytes. *Eur J Immunol* 2013, 43, 1667–75. doi:10.1002/eji.201343312
70. Villar J, Ouaknin L, Cros A, Segura E. Monocytes differentiate along two alternative pathways during sterile inflammation. *EMBO Rep* 2023, 24, e56308. doi:10.15252/embr.202256308
71. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. *Blood* 2010, 116, 3955–63. doi:10.1182/blood-2010-02-266296
72. Varol C, Landsman L, Fogg DK, Greenshtein L, Gildor B, Margalit R, et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. *J Exp Med* 2007, 204, 171–80. doi:10.1084/jem.20061011
73. Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. *J Exp Med* 2017, 214, 1913–23. doi:10.1084/jem.20170355
74. Tak T, Drylewicz J, Conemans L, de Boer RJ, Koenderman L, Borghans JAM, et al. Circulatory and maturation kinetics of human monocyte subsets in vivo. *Blood* 2017, 130, 1474–7. doi:10.1182/blood-2017-03-771261
75. O'Connor KW, Liu T, Kim S, Briseño CG, Georgopoulos K, Murphy TL, et al. Bcl6, Irf2, and Notch2 promote nonclassical monocyte development. *Proc Natl Acad Sci U S A* 2023, 120, e2220853120. doi:10.1073/pnas.2220853120
76. Kim S, Chen J, Ou F, Liu T-T, Jo S, Gillanders WE, et al. Transcription factor C/EBPalpha is required for the development of Ly6C(hi) monocytes but not Ly6C(lo) monocytes. *Proc Natl Acad Sci U S A* 2024, 121, e2315659121. doi:10.1073/pnas.2315659121
77. Gamrekelashvili J, Giagnorio R, Jusoffie J, Soehnlein O, Duchene J, Briseño CG, et al. Regulation of monocyte cell fate by blood vessels mediated by Notch signalling. *Nat Commun* 2016, 7, 12597. doi:10.1038/ncomms12597
78. Gamrekelashvili J, Kapanadze T, Sablotny S, Ratiu C, Dastagir K, Lochner M, et al. Notch and TLR signaling coordinate monocyte cell fate and inflammation. *Elife* 2020, 9, e57007. doi:10.7554/eLife.57007
79. Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. *Nat Immunol* 2011, 12, 778–85. doi:10.1038/ni.2063
80. Tamura A, Hirai H, Yokota A, Kamio N, Sato A, Shoji T, et al. C/EBPbeta is required for survival of Ly6C-monocytes. *Blood* 2017, 130, 1809–18. doi:10.1182/blood-2017-03-772962
81. Roberts ME, Barvalia M, Silva JAFD, Cederberg RA, Chu W, Wong A, et al. Deep phenotyping by mass cytometry and single-cell RNA-sequencing reveals LYN-regulated signaling profiles underlying monocyte subset heterogeneity and lifespan. *Circ Res* 2020, 126, e61–79. doi:10.1161/CIRCRESAHA.119.315708
82. Landsman L, Bar-On L, Zerneck A, Kim K-W, Krauthgamer R, Shagdarsuren E, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. *Blood* 2009, 113, 963–72. doi:10.1182/blood-2008-07-170787
83. Kim KW, Vallon-Eberhard A, Zigmund E, Farache J, Shezen E, Shakhar G, et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. *Blood* 2011, 118, e156–67. doi:10.1182/blood-2011-04-348946
84. Thierry GR, Baudon EM, Bijnen M, Bellomo A, Lagueyrie M, Mondor I, et al. Non-classical monocytes scavenge the growth factor CSF1 from endothelial cells in the peripheral vascular tree to ensure survival and homeostasis. *Immunity* 2024, 57, 2108–2121. doi:10.1016/j.immuni.2024.07.005
85. Shiloh R, Lubin R, David O, Geron I, Okon E, Hazan I, et al. Loss of function of ENT3 drives histiocytosis and inflammation through TLR-MAPK signaling. *Blood* 2023, 142, 1740–51. doi:10.1182/blood.2023020714
86. Schmidl C, Renner K, Peter K, Eder R, Lassmann T, Balwierz PJ, et al.; FANTOM consortium. Transcription and enhancer profiling in human monocyte subsets. *Blood* 2014, 123, e90–9. doi:10.1182/blood-2013-02-484188
87. Patel AA, Yona S. Inherited and environmental factors influence human monocyte heterogeneity. *Front Immunol* 2019, 10, 2581. doi:10.3389/fimmu.2019.02581
88. Christ A, Günther P, Lauterbach MAR, Duester P, Biswas D, Pelka K, et al. Western diet triggers NLRP3-dependent innate immune reprogramming. *Cell* 2018, 172, 162–75.e14. doi:10.1016/j.cell.2017.12.013
89. Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, Chawla A. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. *Science* 2013, 341, 1483–8. doi:10.1126/science.1240636
90. Williams JW, Elvington A, Ivanov S, Kessler S, Luehmann H, Baba O, et al. Thermoneutrality but not UCP1 deficiency suppresses monocyte mobilization into blood. *Circ Res* 2017, 121, 662–76. doi:10.1161/CIRCRESAHA.117.311519
91. Jordan S, Tung N, Casanova-Acebes M, Chang C, Cantoni C, Zhang D, et al. Dietary intake regulates the circulating inflammatory monocyte pool. *Cell* 2019, 178, 1102–14.e17. doi:10.1016/j.cell.2019.07.050
92. Bain CC, Bravo-Blas A, Scott CL, Perdiguero EG, Geissmann F, Henri S, et al. Constant replenishment from circulating monocytes

- maintains the macrophage pool in the intestine of adult mice. *Nat Immunol* 2014, **15**, 929–37. doi:[10.1038/ni.2967](https://doi.org/10.1038/ni.2967)
93. Tamoutounour S, Williams M, Montanana Sanchis F, Liu H, Terhorst D, Malosse C, et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. *Immunity* 2013, **39**, 925–38. doi:[10.1016/j.immuni.2013.10.004](https://doi.org/10.1016/j.immuni.2013.10.004)
 94. McGovern N, Schlitzer A, Gunawan M, Jardine L, Shin A, Poyner E, et al. Human dermal CD14(+) cells are a transient population of monocyte-derived macrophages. *Immunity* 2014, **41**, 465–77. doi:[10.1016/j.immuni.2014.08.006](https://doi.org/10.1016/j.immuni.2014.08.006)
 95. Bonnardel J, T'Jonck W, Gaubomme D, Browaeys R, Scott CL, Martens L, et al. Stellate cells, hepatocytes, and endothelial cells imprint the Kupffer cell identity on monocytes colonizing the liver macrophage niche. *Immunity* 2019, **51**, 638–54.e9. doi:[10.1016/j.immuni.2019.08.017](https://doi.org/10.1016/j.immuni.2019.08.017)
 96. Seidman JS, Troutman TD, Sakai M, Gola A, Spann NJ, Bennett H, et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. *Immunity* 2020, **52**, 1057–74.e7. doi:[10.1016/j.immuni.2020.04.001](https://doi.org/10.1016/j.immuni.2020.04.001)
 97. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* 2014, **159**, 1312–26. doi:[10.1016/j.cell.2014.11.018](https://doi.org/10.1016/j.cell.2014.11.018)
 98. van de Laar L, Saelens W, De Prijck S, Martens L, Scott CL, Van Isterdael G, et al. Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages. *Immunity* 2016, **44**, 755–68. doi:[10.1016/j.immuni.2016.02.017](https://doi.org/10.1016/j.immuni.2016.02.017)
 99. Krow-Lucal ER, Kim CC, Burt TD, McCune JM. Distinct functional programming of human fetal and adult monocytes. *Blood* 2014, **123**, 1897–904. doi:[10.1182/blood-2013-11-536094](https://doi.org/10.1182/blood-2013-11-536094)
 100. Shemer A, Grozovski J, Tay TL, Tao J, Volaski A, Süß P, et al. Engrafted parenchymal brain macrophages differ from microglia in transcriptome, chromatin landscape and response to challenge. *Nat Commun* 2018, **9**, 5206. doi:[10.1038/s41467-018-07548-5](https://doi.org/10.1038/s41467-018-07548-5)
 101. Bennett FC, Bennett ML, Yaqoob F, Mulinyawe SB, Grant GA, Hayden Gephart M, et al. A combination of ontogeny and cns environment establishes microglial identity. *Neuron* 2018, **98**, 1170–83.e8. doi:[10.1016/j.neuron.2018.05.014](https://doi.org/10.1016/j.neuron.2018.05.014)
 102. Cronk JC, Filiano AJ, Louveau A, Marin I, Marsh R, Ji E, et al. Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. *J Exp Med* 2018, **215**, 1627–47. doi:[10.1084/jem.20180247](https://doi.org/10.1084/jem.20180247)
 103. Hume DA. Fate-mapping studies in inbred mice: a model for understanding macrophage development and homeostasis? *Eur J Immunol* 2023, **53**, e2250242. doi:[10.1002/eji.202250242](https://doi.org/10.1002/eji.202250242)
 104. Landsman L, Varol C, Jung S. Distinct differentiation potential of blood monocyte subsets in the lung. *J Immunol* 2007, **178**, 2000–7. doi:[10.4049/jimmunol.178.4.2000](https://doi.org/10.4049/jimmunol.178.4.2000)
 105. Tacke R, Hilgendorf I, Garner H, Waterborg C, Park K, Nowyhed H, et al. The transcription factor NR4A1 is essential for the development of a novel macrophage subset in the thymus. *Sci Rep* 2015, **5**, 10055. doi:[10.1038/srep10055](https://doi.org/10.1038/srep10055)
 106. Carlin LM, Stamatziades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrena G, et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. *Cell* 2013, **153**, 362–75. doi:[10.1016/j.cell.2013.03.010](https://doi.org/10.1016/j.cell.2013.03.010)
 107. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. *Science* 2007, **317**, 666–70. doi:[10.1126/science.1142883](https://doi.org/10.1126/science.1142883)
 108. Cros J, Cagnard N, Woollard K, Patey N, Zhang S-Y, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 2010, **33**, 375–86. doi:[10.1016/j.immuni.2010.08.012](https://doi.org/10.1016/j.immuni.2010.08.012)
 109. Foote JR, Patel AA, Yona S, Segal AW. Variations in the phagosomal environment of human neutrophils and mononuclear phagocyte subsets. *Front Immunol* 2019, **10**, 188. doi:[10.3389/fimmu.2019.00188](https://doi.org/10.3389/fimmu.2019.00188)
 110. Gordon S. Alternative activation of macrophages. *Nat Rev Immunol* 2003, **3**, 23–35. doi:[10.1038/nri978](https://doi.org/10.1038/nri978)
 111. Amorim A, De Feo D, Friebel E, Ingelfinger F, Anderfuhren CD, Krishnarajah S, et al. IFN γ and GM-CSF control complementary differentiation programs in the monocyte-to-phagocyte transition during neuroinflammation. *Nat Immunol* 2022, **23**, 217–28. doi:[10.1038/s41590-021-01117-7](https://doi.org/10.1038/s41590-021-01117-7)
 112. Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD, et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. *Brain* 2009, **132**, 2487–500. doi:[10.1093/brain/awp144](https://doi.org/10.1093/brain/awp144)
 113. Katkar G, Ghosh P. Macrophage states: there's a method in the madness. *Trends Immunol* 2023, **44**, 954–64. doi:[10.1016/j.it.2023.10.006](https://doi.org/10.1016/j.it.2023.10.006)
 114. Nahrendorf M, Swirski FK. Abandoning M1/M2 for a network model of macrophage function. *Circ Res* 2016, **119**, 414–7. doi:[10.1161/CIRCRESAHA.116.309194](https://doi.org/10.1161/CIRCRESAHA.116.309194)
 115. Schneider C, Nobs SP, Kurrer M, Rehrauer H, Thiele C, Kopf M. Induction of the nuclear receptor PPAR- γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. *Nat Immunol* 2014, **15**, 1026–37. doi:[10.1038/ni.3005](https://doi.org/10.1038/ni.3005)
 116. Williams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med* 2013, **210**, 1977–92. doi:[10.1084/jem.20131199](https://doi.org/10.1084/jem.20131199)
 117. Spath S, Komuczki J, Hermann M, Pelczar P, Mair F, Schreiner B, et al. Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system. *Immunity* 2017, **46**, 245–60. doi:[10.1016/j.immuni.2017.01.007](https://doi.org/10.1016/j.immuni.2017.01.007)
 118. Kratoofil RM, Shim HB, Shim R, Lee WY, Labit E, Sinha S, et al. A monocyte-leptin-angiogenesis pathway critical for repair post-infection. *Nature* 2022, **609**, 166–73. doi:[10.1038/s41586-022-05044-x](https://doi.org/10.1038/s41586-022-05044-x)
 119. Chakarov S, Blieriot C, Ginhoux F. Role of adipose tissue macrophages in obesity-related disorders. *J Exp Med* 2022, **219**, e20211948. doi:[10.1084/jem.20211948](https://doi.org/10.1084/jem.20211948)
 120. Chavakis T, Alexaki VI, Ferrante AWJr. Macrophage function in adipose tissue homeostasis and metabolic inflammation. *Nat Immunol* 2023, **24**, 757–66. doi:[10.1038/s41590-023-01479-0](https://doi.org/10.1038/s41590-023-01479-0)
 121. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest* 2003, **112**, 1796–808. doi:[10.1172/JCI19246](https://doi.org/10.1172/JCI19246)
 122. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch U-K, Mack M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. *Nat Neurosci* 2007, **10**, 1544–53. doi:[10.1038/nn2015](https://doi.org/10.1038/nn2015)
 123. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/ iNOS -producing dendritic cells mediate innate immune defense against bacterial infection. *Immunity* 2003, **19**, 59–70. doi:[10.1016/s1074-7613\(03\)00171-7](https://doi.org/10.1016/s1074-7613(03)00171-7)
 124. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. *J Clin Invest* 2006, **116**, 115–24. doi:[10.1172/JCI24335](https://doi.org/10.1172/JCI24335)
 125. Feng B, Jiao P, Nie Y, Kim T, Jun D, van Rooijen N, et al. Clodronate liposomes improve metabolic profile and reduce visceral adipose macrophage content in diet-induced obese mice. *PLoS One* 2011, **6**, e24358. doi:[10.1371/journal.pone.0024358](https://doi.org/10.1371/journal.pone.0024358)
 126. Patel AA, Yona S. Phagocyte development, in *eLS*. 2018. p. 1–13.
 127. Patsouris D, Li P-P, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. *Cell Metab* 2008, **8**, 301–9. doi:[10.1016/j.cmet.2008.08.015](https://doi.org/10.1016/j.cmet.2008.08.015)

128. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science* 1993, **259**, 87–91. doi:10.1126/science.7678183
129. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003, **112**, 1821–30. doi:10.1172/JCI19451
130. Yu M, Zhou H, Zhao J, Xiao N, Roychowdhury S, Schmitt D, et al. MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. *J Exp Med* 2014, **211**, 887–907. doi:10.1084/jem.20131314
131. Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. *Cell Metab* 2014, **20**, 614–25. doi:10.1016/j.cmet.2014.08.010
132. Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, et al. Lipid-associated macrophages control metabolic homeostasis in a trem2-dependent manner. *Cell* 2019, **178**, 686–98.e14. doi:10.1016/j.cell.2019.05.054
133. Hill DA, Lim H-W, Kim YH, Ho WY, Foong YH, Nelson VL, et al. Distinct macrophage populations direct inflammatory versus physiological changes in adipose tissue. *Proc Natl Acad Sci U S A* 2018, **115**, E5096–105. doi:10.1073/pnas.1802611115
134. Stansbury CM, Dotson GA, Pugh H, Rehemtulla A, Rajapakse I, Muir LA. A lipid-associated macrophage lineage rewires the spatial landscape of adipose tissue in early obesity. *JCI Insight* 2023, **8**, e171701. doi:10.1172/jci.insight.171701
135. Sharif O, Brunner JS, Korosec A, Martins R, Jais A, Snijder B, et al. Beneficial metabolic effects of TREM2 in obesity are uncoupled from its expression on macrophages. *Diabetes* 2021, **70**, 2042–57. doi:10.2337/db20-0572
136. Cox N, Crozet L, Holtman IR, Loyher P-L, Lazarov T, White JB, et al. Diet-regulated production of PDGF β by macrophages controls energy storage. *Science* 2021, **373**, eabe9383. doi:10.1126/science.abe9383
137. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2 $^{-/-}$ mice reveals a role for chemokines in the initiation of atherosclerosis. *Nature* 1998, **394**, 894–7. doi:10.1038/29788
138. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. *Mol Cell* 1998, **2**, 275–81. doi:10.1016/s1097-2765(00)80139-2
139. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. *J Clin Invest* 2007, **117**, 185–94. doi:10.1172/JCI28549
140. Williams JW, Zaitsev K, Kim K-W, Ivanov S, Saunders BT, Schrank PR, et al. Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression. *Nat Immunol* 2020, **21**, 1194–204. doi:10.1038/s41590-020-0768-4
141. Quintar A, McArdle S, Wolf D, Marki A, Ehinger E, Vassallo M, et al. Endothelial protective monocyte patrolling in large arteries intensified by western diet and atherosclerosis. *Circ Res* 2017, **120**, 1789–99. doi:10.1161/CIRCRESAHA.117.310739
142. Hilgendorf I, Gerhardt LMS, Tan TC, Winter C, Holderried TAW, Chousterman BG, et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. *Circ Res* 2014, **114**, 1611–22. doi:10.1161/CIRCRESAHA.114.303204
143. Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Herrley E, et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. *Circ Res* 2012, **110**, 416–27. doi:10.1161/CIRCRESAHA.111.253377
144. Thomas GD, Hanna RN, Vasudevan NT, Hamers AA, Romanoski CE, McArdle S, et al. Deleting an Nr4a1 super-enhancer subdomain ablates Ly6C(low) monocytes while preserving macrophage gene function. *Immunity* 2016, **45**, 975–87. doi:10.1016/j.immuni.2016.10.011
145. Zerneck A, Winkels H, Cochain C, Williams JW, Wolf D, Soehnlein O, et al. Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas. *Circ Res* 2020, **127**, 402–26. doi:10.1161/CIRCRESAHA.120.316903
146. Zerneck A, Erhard F, Weinberger T, Schulz C, Ley K, Saliba A-E, et al. Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis. *Cardiovasc Res* 2023, **119**, 1676–89. doi:10.1093/cvr/cvac161
147. Guo X, Li B, Wen C, Zhang F, Xiang X, Nie L, et al. TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis. *Cell Mol Life Sci* 2023, **80**, 137. doi:10.1007/s00018-023-04786-9
148. Patterson MT, Firulyova MM, Xu Y, Hillman H, Bishop C, Zhu A, et al. Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis. *Nat Cardiovasc Res* 2023, **2**, 1015–31. doi:10.1038/s44161-023-00354-3
149. Hardtner C, Kumar A, Ehlert CA, Vico TA, Starz C, von Ehr A, et al. A comparative gene expression matrix in ApoE-deficient mice identifies unique and atherosclerotic disease stage-specific gene regulation patterns in monocytes and macrophages. *Atherosclerosis* 2023, **371**, 1–13. doi:10.1016/j.atherosclerosis.2023.03.006
150. Dib L, Koneva LA, Edsfeldt A, Zurke Y-X, Sun J, Nitulescu M, et al. Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis increasing the risk of cerebrovascular complications. *Nat Cardiovasc Res* 2023, **2**, 656–72. doi:10.1038/s44161-023-00295-x
151. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. *Proc Natl Acad Sci U S A* 2004, **101**, 10679–84. doi:10.1073/pnas.0403249101
152. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of interleukin-1 β decreases the severity of atherosclerosis in ApoE-deficient mice. *Arterioscler Thromb Vasc Biol* 2003, **23**, 656–60. doi:10.1161/01.ATV.0000064374.15232.C3
153. Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. *Science* 2016, **352**, aaf1098. doi:10.1126/science.aaf1098
154. Cirovic B, de Bree LCJ, Groh L, Blok BA, Chan J, van der Velden WJFM, et al. BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment. *Cell Host Microbe* 2020, **28**, 322–34.e5. doi:10.1016/j.chom.2020.05.014
155. Bekkering S, Quintin J, Joosten LAB, van der Meer JWM, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. *Arterioscler Thromb Vasc Biol* 2014, **34**, 1731–8. doi:10.1161/ATVBAHA.114.303887
156. Seijkens T, Hoeksema MA, Beckers L, Smeets E, Meiler S, Levels J, et al. Hypercholesterolemia-induced priming of hematopoietic stem and progenitor cells aggravates atherosclerosis. *FASEB J* 2014, **28**, 2202–13. doi:10.1096/fj.13-243105
157. Ouyang Z, Zhong J, Shen J, Zeng Y. The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis. *Front Physiol* 2023, **14**, 1179828. doi:10.3389/fphys.2023.1179828
158. Hernandez GE, Ma F, Martinez G, Firozabadi NB, Salvador J, Juang LJ, et al. Aortic intimal resident macrophages are essential for maintenance of the non-thrombogenic intravascular state. *Nat Cardiovasc Res* 2022, **1**, 67–84. doi:10.1038/s44161-021-00006-4

159. Solis AG, Bielecki P, Steach HR, Sharma L, Harman CCD, Yun S, et al. Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity. *Nature* 2019, 573, 69–74. doi:10.1038/s41586-019-1485-8
160. Xu H, He Y, Hong T, Bi C, Li J, Xia M. Piezo1 in vascular remodeling of atherosclerosis and pulmonary arterial hypertension: a potential therapeutic target. *Front Cardiovasc Med* 2022, 9, 1021540. doi:10.3389/fcvm.2022.1021540
161. Bruhl H, Cihak J, Plachý J, Kunz-Schughart L, Niedermeier M, Denzel A, et al. Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. *Arthritis Rheum* 2007, 56, 2975–85. doi:10.1002/art.22854
162. Saadane A, Veenstra AA, Minns MS, Tang J, Du Y, Abubakr Elghazali F, et al. CCR2-positive monocytes contribute to the pathogenesis of early diabetic retinopathy in mice. *Diabetologia* 2023, 66, 590–602. doi:10.1007/s00125-022-05860-w
163. Rousselle A, Kettritz R, Schreiber A. Monocytes promote crescent formation in anti-myeloperoxidase antibody-induced glomerulonephritis. *Am J Pathol* 2017, 187, 1908–15. doi:10.1016/j.ajpath.2017.05.003
164. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. *J Exp Med* 1999, 190, 1813–24. doi:10.1084/jem.190.12.1813
165. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FMV. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. *Nat Neurosci* 2011, 14, 1142–9. doi:10.1038/nn.2887
166. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. *Blood* 2009, 113, 3190–7. doi:10.1182/blood-2008-07-168575
167. Wolf Y, Shemer A, Polonsky M, Gross M, Mildner A, Yona S, et al. Autonomous TNF is critical for in vivo monocyte survival in steady state and inflammation. *J Exp Med* 2017, 214, 905–17. doi:10.1084/jem.20160499
168. Locatelli G, Theodorou D, Kendirli A, Jordão MJC, Staszewski O, Phulphagar K, et al. Mononuclear phagocytes locally specify and adapt their phenotype in a multiple sclerosis model. *Nat Neurosci* 2018, 21, 1196–208. doi:10.1038/s41593-018-0212-3
169. McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. *J Exp Med* 2001, 194, 873–82. doi:10.1084/jem.194.7.873
170. Okuda Y, Sakoda S, Bernard CC, Fujimura H, Saeki Y, Kishimoto T, et al. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. *Int Immunol* 1998, 10, 703–8. doi:10.1093/intimm/10.5.703
171. Becher B, Segal BM. T(H)17 cytokines in autoimmune neuro-inflammation. *Curr Opin Immunol* 2011, 23, 707–12. doi:10.1016/j.coi.2011.08.005
172. Kruglov AA, Lampropoulou V, Fillatreau S, Nedospasov SA. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. *J Immunol* 2011, 187, 5660–70. doi:10.4049/jimmunol.1100663
173. Croxford AL, Lanzinger M, Hartmann FJ, Schreiner B, Mair F, Pelczar P, et al. The cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity. *Immunity* 2015, 43, 502–14. doi:10.1016/j.immuni.2015.08.010
174. Furtado GC, Piña B, Tacke F, Gaupp S, van Rooijen N, Moran TM, et al. A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells. *J Immunol* 2006, 177, 6871–9. doi:10.4049/jimmunol.177.10.6871
175. Dalton DK, Wittmer S. Nitric-oxide-dependent and independent mechanisms of protection from CNS inflammation during Th1-mediated autoimmunity: evidence from EAE in iNOS KO mice. *J Neuroimmunol* 2005, 160, 110–21. doi:10.1016/j.jneuroim.2004.11.004
176. Brennan M, Gaur A, Pahuja A, Lulis AJ, Reynolds WF. Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis. *J Neuroimmunol* 2001, 112, 97–105. doi:10.1016/s0165-5728(00)00392-1
177. Mendiola AS, Ryu JK, Bardehle S, Meyer-Franke A, Ang KK, Wilson C, et al. Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation. *Nat Immunol* 2020, 21, 513–24. doi:10.1038/s41590-020-0654-0
178. Keller CW, Kotur MB, Mundt S, Dokalis N, Ligeon L-A, Shah AM, et al. CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation. *Autophagy* 2021, 17, 1244–58. doi:10.1080/15548627.2020.1756678
179. Pare A, Mailhot B, Lévesque SA, Juzwik C, Ignatius Arokia Doss PM, Lécuyer M-A, et al. IL-1beta enables CNS access to CCR2(hi) monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells. *Proc Natl Acad Sci U S A* 2018, 115, E1194–203. doi:10.1073/pnas.1714948115
180. Ronchi F, Basso C, Preite S, Reboldi A, Baumjohann D, Perlini L, et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1beta production by myeloid cells. *Nat Commun* 2016, 7, 11541. doi:10.1038/ncomms11541
181. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1992, 176, 1693–702. doi:10.1084/jem.176.6.1693
182. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *J Exp Med* 1994, 179, 1109–18. doi:10.1084/jem.179.4.1109
183. Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. *Nat Rev Immunol* 2017, 17, 349–62. doi:10.1038/nri.2017.28
184. Coillard A, Segura E. Antigen presentation by mouse monocyte-derived cells: re-evaluating the concept of monocyte-derived dendritic cells. *Mol Immunol* 2021, 135, 165–9. doi:10.1016/j.molimm.2021.04.012
185. Tang-Huau TL, Segura E. Human in vivo-differentiated monocyte-derived dendritic cells. *Semin Cell Dev Biol* 2019, 86, 44–9. doi:10.1016/j.semcdb.2018.02.018
186. Flores-Langarica A, Marshall JL, Bobat S, Mohr E, Hitchcock J, Ross EA, et al. T-zone localized monocyte-derived dendritic cells promote Th1 priming to Salmonella. *Eur J Immunol* 2011, 41, 2654–65. doi:10.1002/eji.201141440
187. Walkim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. *Science* 2008, 319, 198–202. doi:10.1126/science.1151869
188. Kool M, Soullé T, van Nimwegen M, Willart MAM, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. *J Exp Med* 2008, 205, 869–82. doi:10.1084/jem.20071087
189. Ji Q, Castelli L, Goverman JM. MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8(+) T cells. *Nat Immunol* 2013, 14, 254–61. doi:10.1038/ni.2513
190. Zigmund E, Varol C, Farache J, Elmaliah E, Satpathy AT, Friedlander G, et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. *Immunity* 2012, 37, 1076–90. doi:10.1016/j.immuni.2012.08.026
191. Bosteels C, Scott CL. Transcriptional regulation of DC fate specification. *Mol Immunol* 2020, 121, 38–46. doi:10.1016/j.molimm.2020.02.021
192. Min J, Yang D, Kim M, Haam K, Yoo A, Choi J-H, et al. Inflammation induces two types of inflammatory dendritic cells in inflamed lymph nodes. *Exp Mol Med* 2018, 50, e458. doi:10.1038/emmm.2017.292

193. Hunter, J., *A Treatise on the Blood, inflammation and Gunshot Wounds*. London: George Nicol, 1794.
194. Ebert RH, Florey HW. The extravascular development of the monocyte observed in vivo. *Br J Exp Pathol* 1939, 20, 342–56.
195. Volkman A, Gowans JL. The origin of macrophages from bone marrow in the rat. *Br J Exp Pathol* 1965, 46, 62–70.
196. Wulff HR, Sparrevoth S. The origin of mononuclear cells in human skin windows. *Acta Pathol Microbiol Scand* 1966, 68, 401–7. doi:10.1111/apm.1966.68.3.401
197. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. *Science* 2011, 332, 1284–8. doi:10.1126/science.1204351
198. Newson J, Stables M, Karra E, Arce-Vargas F, Quezada S, Motwani M, et al. Resolution of acute inflammation bridges the gap between innate and adaptive immunity. *Blood* 2014, 124, 1748–64. doi:10.1182/blood-2014-03-562710
199. Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J, et al. Transcriptomic analyses of murine resolution-phase macrophages. *Blood* 2011, 118, e192–208. doi:10.1182/blood-2011-04-345330
200. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. *Proc Natl Acad Sci USA* 2012, 109, E3186–95.
201. Auffray C, Fogg DK, Narni-Mancinelli E, Senechal B, Trouillet C, Saederup N, et al. CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. *J Exp Med* 2009, 206, 595–606. doi:10.1084/jem.20081385
202. Rodero MP, Licata F, Poupel L, Hamon P, Khosrotehrani K, Combadiere C, et al. In vivo imaging reveals a pioneer wave of monocyte recruitment into mouse skin wounds. *PLoS One* 2014, 9, e108212. doi:10.1371/journal.pone.0108212
203. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. *J Exp Med* 2007, 204, 1057–69. doi:10.1084/jem.20070075
204. Dal-Secco D, Wang J, Zeng Z, Kolaczowska E, Wong CHY, Petri B, et al. A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. *J Exp Med* 2015, 212, 447–56. doi:10.1084/jem.20141539
205. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. *J Exp Med* 2007, 204, 3037–47. doi:10.1084/jem.20070885
206. London A, Itskovich E, Benhar I, Kalchenko V, Mack M, Jung S, et al. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. *J Exp Med* 2011, 208, 23–39. doi:10.1084/jem.20101202
207. Zigmund E, Samia-Grinberg S, Pasmanik-Chor M, Brazowski E, Shibolet O, Halpern Z, et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury. *J Immunol* 2014, 193, 344–53. doi:10.4049/jimmunol.1400574
208. Graubardt N, Vugman M, Mouhadeb O, Caliani G, Pasmanik-Chor M, Reuveni D, et al. Ly6C(hi) monocytes and their macrophage descendants regulate neutrophil function and clearance in acetaminophen-induced liver injury. *Front Immunol* 2017, 8, 626. doi:10.3389/fimmu.2017.00626
209. Askenase MH, Han S-J, Byrd AL, Morais da Fonseca D, Bouldoux N, Wilhelm C, et al. Bone-marrow-resident NK cells prime monocytes for regulatory function during infection. *Immunity* 2015, 42, 1130–42. doi:10.1016/j.immuni.2015.05.011
210. Egawa M, Mukai K, Yoshikawa S, Iki M, Mukaida N, Kawano Y, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. *Immunity* 2013, 38, 570–80. doi:10.1016/j.immuni.2012.11.014
211. Sharma A, Blériot C, Currenti J, Ginhoux F. Oncofetal reprogramming in tumour development and progression. *Nat Rev Cancer* 2022, 22, 593–602. doi:10.1038/s41568-022-00497-8
212. Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Núñez NG, et al. Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer. *Cell* 2022, 185, 1189–207.e25. doi:10.1016/j.cell.2022.02.021
213. Park MD, Reyes-Torres I, LeBerichel J, Hamon P, LaMarche NM, Hegde S, et al. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. *Nat Immunol* 2023, 24, 792–801. doi:10.1038/s41590-023-01475-4
214. Zhu Y, Herndon JM, Sojka DK, Kim K-W, Knolhoff BL, Zuo C, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. *Immunity* 2017, 47, 597–338 e6. doi:10.1016/j.immuni.2017.08.018
215. Dunsmore G, Guo W, Li Z, Bejarano DA, Pai R, Yang K, et al. Timing and location dictate monocyte fate and their transition to tumor-associated macrophages. *Sci Immunol* 2024, 9, eadk3981.
216. Patterson MT, Burrack AL, Xu Y, Hickok GH, Schmiechen ZC, Becker S, et al. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. *Cell Rep* 2023, 42, 112732. doi:10.1016/j.celrep.2023.112732
217. De Palma M, Venneri MA, Galli R, Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell* 2005, 8, 211–26. doi:10.1016/j.ccr.2005.08.002
218. Xue R, Sheng Y, Duan X, Yang Y, Ma S, Xu J, et al. Tie2-expressing monocytes as a novel angiogenesis-related cellular biomarker for non-small cell lung cancer. *Int J Cancer* 2021, 148, 1519–28. doi:10.1002/ijc.33381
219. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. *Blood* 2007, 109, 5276–85. doi:10.1182/blood-2006-10-053504
220. Avraham-Davidi I, Yona S, Grunewald M, Landsman L, Cochain C, Silvestre JS, et al. On-site education of VEGF-recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells. *J Exp Med* 2013, 210, 2611–25. doi:10.1084/jem.20120690
221. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. *Cancer Res* 2010, 70, 7465–75. doi:10.1158/0008-5472.CAN-10-1439
222. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan L-J, et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. *J Clin Invest* 2010, 120, 2699–714. doi:10.1172/JCI39506
223. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passequé E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. *Cancer Cell* 2008, 13, 206–20. doi:10.1016/j.ccr.2008.01.034
224. Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. *Cell* 2021, 184, 792–809.e23. doi:10.1016/j.cell.2021.01.010
225. Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O'Brien SA, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. *Cell* 2020, 181, 442–59.e29. doi:10.1016/j.cell.2020.03.048

226. Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. *Nat Commun* 2022, **13**, 1742. doi:[10.1038/s41467-022-29366-6](https://doi.org/10.1038/s41467-022-29366-6)
227. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. *Cell* 2017, **169**, 750–65.e17. doi:[10.1016/j.cell.2017.04.014](https://doi.org/10.1016/j.cell.2017.04.014)
228. Saba Y, Aizenbud I, Matanes D, Koren N, Barel O, Zubeidat K, et al. Early antitumor activity of oral Langerhans cells is compromised by a carcinogen. *Proc Natl Acad Sci U S A* 2022, **119**, e2118424119. doi:[10.1073/pnas.2118424119](https://doi.org/10.1073/pnas.2118424119)
229. Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. *Cell* 2020, **182**, 872–85.e19. doi:[10.1016/j.cell.2020.06.032](https://doi.org/10.1016/j.cell.2020.06.032)
230. Kirschenbaum D, Xie K, Ingelfinger F, Katzenelenbogen Y, Abadie K, Look T, et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. *Cell* 2024, **187**, 149–65.e23. doi:[10.1016/j.cell.2023.11.032](https://doi.org/10.1016/j.cell.2023.11.032)
231. Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. *Cell* 2020, **182**, 886–900.e17. doi:[10.1016/j.cell.2020.07.013](https://doi.org/10.1016/j.cell.2020.07.013)
232. Mulder K, Patel AA, Kong WT, Piot C, Halitzki E, Dunsmore G, et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. *Immunity* 2021, **54**, 1883–900.e5. doi:[10.1016/j.immuni.2021.07.007](https://doi.org/10.1016/j.immuni.2021.07.007)
233. Caronni N, La Terza F, Vittoria FM, Barbiera G, Mezzananza L, Cuzzola V, et al. IL-1beta(+) macrophages fuel pathogenic inflammation in pancreatic cancer. *Nature* 2023, **623**, 415–22. doi:[10.1038/s41586-023-06685-2](https://doi.org/10.1038/s41586-023-06685-2)
234. Das S, Shapiro B, Vucic EA, Vogt S, Bar-Sagi D. Tumor cell-derived IL1beta promotes desmoplasia and immune suppression in pancreatic cancer. *Cancer Res* 2020, **80**, 1088–101. doi:[10.1158/0008-5472.CAN-19-2080](https://doi.org/10.1158/0008-5472.CAN-19-2080)
235. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, et al. Obesity-induced inflammation and resistance to chemotherapy. *Cancer Discov* 2016, **6**, 852–69. doi:[10.1158/2159-8290.CD-15-1177](https://doi.org/10.1158/2159-8290.CD-15-1177)
236. Zhang D, Li L, Jiang H, Wang-Gillam A, Yu J, Head R, et al. Tumor-stroma IL1beta-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. *Cancer Res* 2018, **78**, 995–995. doi:[10.1158/1538-7445.am2018-995](https://doi.org/10.1158/1538-7445.am2018-995)
237. Lan Y, Zhang X, Liu S, Guo C, Jin Y, Li H, et al. Fate mapping of Spp1 expression reveals age-dependent plasticity of disease-associated microglia-like cells after brain injury. *Immunity* 2024, **57**, 349–63.e9. doi:[10.1016/j.immuni.2024.01.008](https://doi.org/10.1016/j.immuni.2024.01.008)
238. Shechter R, London A, Varol C, Raposo C, Cusimano M, Yovel G, et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. *PLoS Med* 2009, **6**, e1000113. doi:[10.1371/journal.pmed.1000113](https://doi.org/10.1371/journal.pmed.1000113)